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This dissertation concerns the development of a synthetic route towards novel cysteine-based         
glycan-binding probes, for incorporation into glycoarrays and or similar applications used in 
assays of glycan-recognition phenomena.                   
The need to systematically characterize the glycome and decipher the range of glycosylation 
patterns found in living cells, has prompted the development of molecular tools such                        
as glycoarrays and related systems for immobilizing defined carbohydrate structures.                          
The preparation of these probes requires access to building blocks where the core structure has 
defined glycans together with appropriate linkers, and the amino acid cysteine is explored here 
as one such structure. 
In particular, this dissertation describes the synthesis of a S-glucosylcysteine derivative SGC, or 
methyl N-(6-aminohexanoyl)-S-(β-D-glucopyranosyl)-L-cysteinate trifluoroacetate 67, as well as 
its 2-acetamido analogue SAGC, or methyl N-(6-aminohexanoyl)-S-(2-acetamido-2-deoxy-β-D-
glucopyranosyl)-L-cysteinate trifluoroacetate 74. 
The first approach involved initial preparation of N-(4-azidobutanoyl)-L-cysteine 12 and 
attempted reaction of this with 1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose 3 to form the initial 
target of this dissertation, bis-glucoside 13. This was not successful, but repetition of the 
reported reaction involving the use of N-acetyl-L-cysteine 4 provided a modest yield of      
partially purified bis-glucosyl cysteine (BGC, 1). A mechanism for this one-pot, sequential                               
bis-glucosylation is proposed. 
The limitations of the one-pot procedure led to investigation of alternative methods for               
the step-wise introduction of sugar units to the cysteine core. For this purpose the cysteine 
derivative, methyl N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-L-cysteinate 40, was prepared 
and reacted with 3 to obtain a fully protected precursor of the target SGC. However, 
inefficiencies in this procedure led to investigation of an alternative strategy for preparation             
of SGC. 





This involved initial preparation of 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranose 21, reaction 
of this with methyl (R)-2-((tert-butoxycarbonyl)amino)-3-iodopropanoate 60, followed by N-Boc 
deprotection and then formation of an N-acyl derivative by reaction with 2,5-dioxopyrrolidin-1-
yl 6-((tert-butoxycarbonyl)amino)hexanoate 45. A final de-O-acetylation and N-Boc deprotection 
gave the target SGC 67. A similar sequence starting with 2-acetamido-3,4,6-tri-O-acetyl-2-
deoxy-1-thio-β-D-glucopyranose 71 gave the SAGC analogue 74.  
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1.1. The importance of glycoscience 
In the biological scientific community a great emphasis has been placed on the fields of 
genomics and proteomics to better understand the intricacies of a living organism. In essence 
they hope to achieve a better understanding of the central dogma, which is the flow of genetic 
information from nucleic acids to fully functional proteins. Despite this, more than 50 % of              
all proteins are found as glycoproteins (a generic term for carbohydrate-protein conjugates).1    
This is manifest in a range of glycan structures such as proteoglycans, glycolipids and 
glycoproteins on the surfaces of or associated with living cells.2,3 In turn these carbohydrate 
structures, or glycans, affect various facets of their conjugated proteins character such as 
folding, stability, trafficking and secretion, all of which contribute to a biologically viable 
protein.1 Furthermore specific glycosylation patterns on the surfaces of cells can serve as 
biomarkers to identify either the early onset or stage of certain diseases. This is exemplified in 
diseases such as cancer, diabetes and neurodegenerative disorders, all of which feature 
unnatural glycosylation in the disease state.2,4 Hence, if the structural identities of these 
carbohydrate molecules are known, then their role in either the promotion or inhibition of 
protein function and disease can be better assessed.  
The role of these glycans is the domain of glycoscience; this has emerged as a versatile field 
that strives to better understand the structural and functional properties of glycans in 
biological systems. Furthermore, this research field can be broken down into the two          
subdisciplines of glycobiology and glycochemistry, where the former, despite enormous 
progress, is limited by the current molecular tools available to it. This together with 
difficulties encountered in the characterization of complex glycan structures and the 
availability of pure carbohydrates is currently hindering the development of this field.2,5 
Overcoming these challenges will require new and refined molecular tools, structures 
designed for specific tasks and ones that are robust enough to address current and future 
challenges in the field of glycoscience.  





1.2. A brief account of the human glycome 
  
The structural diversity of the cellular glycome dwarfs both the genome and proteome and is 
estimated to consist of approximately 100,000-500,000 unique glycan structures.3 The existence 
of this diversity of structures is primarily attributed to two factors. Firstly, the cell specific 
expression of different glycosyltransferases, enzymes which mediate the non-template 
biosynthesis of glycans, results in different glycans being expressed on the cellular surface of 
specific cells within an organism.3,6 Secondly, nucleic acid and protein biomolecules only occur 
as linear structures, whereas carbohydrate biomolecules can occur as both linear and branched 
structures, with monomers linked in either α- or β-configurations and thus drastically increasing 
the number of possible glycan structures. One such structure is depicted (Figure 1) as an 
illustrative example.6 In addition to the above, the biosynthesized glycans will often suffer from 
incomplete glycosylation and undergo post-biosynthetic modifications such as acetylation, 
sulfation and phosphorylation at the terminal ends, further complicating the number of glycan 
structures.3,6 Thankfully, the relevant interactions that take place between complex glycan 
structures and their targeted antigens often only take place at the terminal ends of the unique 
glycan structures, thus greatly reducing the number of structural variations that need now be 




Figure 1: The 4-sulfated LDN biantennary N-glycan used as an illustrative example to highlight the complexity of 
glycans found in the human glycome. The sites at which post-sulfation took place (highlighted in red) and the 
glycan determinant (encircled in blue) of the biantennary N-glycan are also shown.6 





In a recent review by Cummings (2009)6 the human glycome (which encompasses both 
glycoproteins and glycolipids) has been estimated to consist of approximately 7,000 unique 
glycan determinants. A more in depth account of the above glycans and their subclasses is 
beyond the scope of this project, which has its basis on the serendipitous discovery of a 
structure which has potential for a range of specific uses in glycoscience. 
 
1.3. A serendipitous discovery 
  
As stated earlier, the advent of new molecular tools is often spurred on by a particular challenge 
faced in biology. However, at times empirical findings tend to spur on the development of 
molecular tools that may or may not address a particular issue, such as disease. Such is the case 
for the focus of this project. A serendipitous discovery by researchers at the Tshwane University 
of Technology (TUT) gave rise to a novel molecule termed bis-glucosyl cysteine* (BGC, 1)    
depicted in Scheme 1.7 This discovery took place during work conducted by Nokwequ et al. in 
which they were preparing analogues of mycothiol, a metabolite implicated in the defensive 
strategies of Mycobacteria. More specifically, they were attempting to optimize the yield              
of N-acetyl-S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-L-cysteine 2 by reacting an excess 
1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose 3 with N-acetyl-L-cysteine 4 in the presence of SnCl4 




Scheme 1: The reaction conditions required to form 1 and 2 at room temperature. The common β-thioglucoside 
linkage (highlighted in blue) and unusual α-glucosyl ester linkage (highlighted in red) of 1 are also shown.7  
*Note in instances where a starting reagent or targeted molecule (in this study) is not referred to by their IUPAC name when first 
tintroduced, in text, then their IUPAC name will be stated here in the footer. 
  IUPAC name: N-acetyl-S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-L-cysteinate (1) 
    
 





Rather than obtaining the desired product 2 in higher yields, it was found that these conditions 
lead to the serendipitous formation of 1 instead. The structure of 1 seems unique, in that it 
incorporates both a β-thioglucoside linkage and a rather unusual α-glucosyl ester linkage. This is 
of interest as the stereoselective formation of a 1,2-cis-α-glucosyl ester linkage remains a 
significant challenge in glycochemistry and the one-step installation of two sugar units in the 
same molecule in two different configurations is unprecedented. Thus in the ensuing discussion, 
an argument is developed for the desirability of embarking on an in depth investigation for the 
use of the BGC scaffold as an enabling tool in the field of glycoscience. 
 
1.4. Potential for BGC as an enabling tool in the field of glycoscience.  
BGC, or more specifically its de-O-acetylated analogue, is a novel structure in a biologically 
important class of molecules, the glycopeptides. To date relatively little interest has been shown 
in the use of cysteine as a scaffold in synthetic glycopeptides such as glycoclusters, molecular 
tools used to study the multivalent effects of carbohydrate-protein interactions.8 Two such 
clusters are the Lindhorst 6 and Dondoni 7 glycoclusters, shown alongside a potential BGC 
glycocluster 5 in Figure 2.8,9 
 
 
    
Figure 2: A comparison of a potential de-O-acetylated BGC glycocluster 5 with selected, cysteine-based 
glycoclusters 6 and 7. The common cysteine core (encircled in blue) is also shown.8,9  





In addition to its potential use as a glycocluster, BGC also bears a striking resemblance to other 
important glycans, prompting speculation that BGC could be a template for new bioactive 
analogues. In particular, it shows similarities to a family of glycolipids termed glycosylceramides 
that inter alia help regulate the immune system via their interaction with invariant natural killer 
T cells (iNKTC).10 The basic structure of a glycosylceramide consists of a phytosphingosine 
ceramide backbone that is linked to a glycan in either an α- or β-configuration. The most 
extensively studied of these glycosylceramides is α-galactosylceramide (α-GalCer, 8) depicted in 
Figure 3.10 This is partly due to its potent anti-tumour activity but primarily due its recognition 
by iNKTC only, as it is a CD1d-restricted antigen. These iNKTC and 8 have since been implicated 
in a variety of pathogenic infections and auto-immune diseases; such as lupus, multiple 
sclerosis, asthma and type I diabetes. In addition, structure activity relationships conducted on 
8 have highlighted that the presence of a hydroxyl group at C-3’ and long acyl lipid tail to be 
crucial for its anti-tumour activity.10 With this in mind, a modified version of BGC is re-imagined 
(Figure 3), in which global deacetylation and the addition of a lipophilic tail to the                     
nitrogen of BGC has taken place to afford BGC ceramide 9. This rendered derivative 9 bears a 
resemblance to 8, making it an ideal candidate to be probed for anti-tumour activity                         




Figure 3: A re-imagined form of BGC as a BGC ceramide 9; depicted together with the foremost studied              
glycosylceramide, α-GalCer 8. The C-3’ hydroxyl group (highlighted in red) and the acyl lipid tail (highlighted in blue) 
play a crucial role in the efficacy of α-GalCer 8 as an anti-tumour agent.10 





One of the most well established tools currently used for mapping glycan-binding specificity are 
glycoarrays. They are generally prepared by taking defined glycans bearing suitable        
terminally-functionalized tethers and binding them onto an active surface or biopolymer.2–4     
This is followed by overlaying them with specific glycan-binding entities and the subsequent 
visualization of binding and recognition phenomena using a host of spectroscopic techniques. 
An illustration of this is provided (Scheme 2), which depicts the possibility of using                        
deacetylated BGC derivatives in glycoarray fabrication. The first process (A) involves taking a 
globally deacetylated form of BGC 10 and attaching a suitable tether to the free amino group to 
afford the glycan-binding probe 11. The second process (B) then involves the covalent 
attachment of 11, having an appropriate functional group at the tether terminus, to an 
appropriate surface. The final process (C) will then involve screening a variety of carbohydrate-
binding proteins (CBPs) and assaying any binding specificities to either one of the sugar units. 
 
 
    
Scheme 2: Processes A, B and C required for the conversion of a modified form of BGC 10 into a novel glycoarray. 





With all of the above in mind, the potential scope of the BGC scaffold as a new and innovative 
enabling tool in glycoscience is indeed a desirable one. A common feature in the                   
above-mentioned examples is the need for the attachment of the tether to the amine 
functionality in cysteine, such as through an acyl linkage. Thus this project will focus on the 
establishment of efficient methods for the preparation of N-acyl cysteine derivatives such as 11 
depicted above in Scheme 2. Once this has been achieved, and the possibility of attachment to 
surfaces has been demonstrated, it will be possible to extend the work to the development of 
novel glycoarrays and testing these for use in carbohydrate-recognition assays, in collaboration 
with research groups at the Alberta Glycomics Centre in Canada and the Centre de Recherches 
sur les Macromolecules Végétales (CERMAV) in France. This would of course require some 
significant further developments, including establishing the possibility of preparing analogues of 
11 which incorporate a range of sugar units other than glucopyranose. 
 
1.5. Glycoarrays an indispensable tool in glycoscience 
Glycoarrays are formally defined as two-dimensional microarrays that are composed of 
structurally different glycans adhered to a solid support surface.2 As stated earlier, the enormity 
of the glycome poses a massive obstacle in systematically deciphering the abundance of 
glycosylation patterns found on or associated with living cells. Up until the early 21st century, 
glycoscientists relied heavily upon biochemical tools in order to study theses glycosylation 
patterns; as the genetic tools available at the time gave limited information in glycomics.2,4 
However, these tools were often time and material consuming, limiting the rate at which 
patterns could be deciphered.4 With no immediate solution, at hand, glycoscientists turned 
their attention to developing a glycan-based microarray (glycoarray) technology; due to the 
success of DNA and recombinant-protein microarray platforms in genomics and proteomics 
respectively.3 This choice in technology paid dividends, as glycoarrays provided a new             
high-throughput method that allowed for the systematic screening of carbohydrate-processing 
enzyme (CPE) activities and CBP interactions both quantitatively and qualitatively.4 In addition 
to this, glycoarrays also circumvented the need for copious amount of glycan material, thus 
effectively allowing for the demands of glycobiologists to be met by synthetic glycochemists.2,4 





Since their inception glycoarrays have found key applications in areas such as lectin binding, 
antibody binding, cell adhesion, enzyme specificity and pathogenic identification.2–4 A more 
detailed account on the applications of glycoarrays is beyond the scope of the project.     
However a key feature that needs to be taken into account when designing a glycan-binding 
probe is the immobilization strategy to be used. 
 
1.5.1. Glycoarray immobilization 
 
As stated earlier a key pre-requisite to the design of glycoarrays is the selection of an 
appropriate functional group on the glycan probe being compatible with the solid array surface. 
To date, two broad strategies for the immobilization of glycan entities to a solid support surface 
have been developed in order to achieve this, namely non-covalent and covalent 
immobilization. In either strategy the actual immobilization can be achieved via an automated 
printing approach or the more common manual binding approach. It must be re-iterated, 
however, that the focus of this project pertains to the synthesis of the glycan probe and not its 
actual immobilization to the array surface. Hence, only an informative account of the covalent 
and non-covalent immobilization strategies used in glycoarray fabrication is given below.2–4 
 
1.5.1.1. Non-covalent immobilization strategies 
Over the years a large number of covalent and non-covalent methods have been developed            
in order to attain the desired glycoarray. Some of the first non-covalent methods                         
reported, involved the immobilization of polysaccharides, proteoglycans and neoglycoproteins 
to either nitrocellulose or oxidized polystyrene surfaces via mixed hydrophobic and hydrophilic 
interactions. This method was later expanded to the use of electrostatic (A), fluorophilic (B), 
biotin-streptavidin and recently complementary DNA hybridization (C) interactions as shown 
below in Figure 4.3,4 Each subsequent strategy overcame the limitations of their respective 
predecessor. Albeit a useful strategy, a common pitfall to the non-covalent approach is that the 
glycan probes are randomly orientated on the array surface, a subtle discrepancy that ultimately 
hampers the efficiency to which the recognition event under investigation can take place.2–4 






Figure 4: A comparison of non-covalent and covalent immobilization strategies used to array glycan probes        
(blue and red spheres) on a solid support surface.3,4 
 
 
Strategies for the covalent immobilization of glycan probes to an array surface emerged soon 




1.5.1.2. Covalent immobilization strategies 
Glycoarrays which are assembled via covalent immobilization are more uniformly orientated 
due to being specifically bound to the solid support surface. This subtle difference allows for the 
glycan probe to better recognize the CBP under investigation.2–4 This method requires only that 
compatible functional groups be present on the solid support surface and linker molecule, prior 
to immobilization. Currently the foremost covalent methods exploit the use of; Huisgen-type 
1,3-dipolar chemistry (D), thiol-malemide ligation chemistry (E) and peptide ligation chemistry 
(F) as shown in Figure 4.3,4  





Some of the early work conducted in covalent glycoarray fabrication, made use of                   
thiol-malemide ligation chemistry (E) in order to help elucidate the binding epitope of 
cyanovirin-N.3 This virucidal protein is produced by the cyanobacterium Nostoc ellipsosporum 
and is a powerful inhibitor of numerous viruses including HIV.11 Although the use of thiol 
chemistry remains a popular choice in glycoarray fabrication, the robust nature of amine 
chemistry has resulted in it being the more widely adopted method due to its compatibility with 
a plethora of array surfaces which can be extended to affinity chromatography. However, a 
major limitation to covalent immobilization is the actual synthesis of the glycan probe since this 
will often require the introduction of a suitably functionalized tether molecule to the glycan         
of interest, often requiring several steps together with difficulties encountered during 
purification.4 In addition to this, the selected functional group needs to be robust enough to 
undergo further derivatization in the event that access to an appropriate array surface is 
limited. An alternative approach to the above approaches, which seeks to circumvent this 
obstacle, is photoimmobilization chemistry. This technique makes use of a photoreactive 
functionalized surface, to which untethered glycan probes are then covalently attached to by 
means of a photochemical reaction. A representative example of this is shown above (Figure 4) 
which makes use of aryl-3-(trifluoromethyl)diazirine photochemistry (G) in order to covalently 
attach the glycan probe to the array surface.3  
Once the glycan probe has been selectively attached to the array surface, the glycoarray can 
then be used to probe for CBP and CPE phenomena using a variety of spectroscopic and 
spectrometric techniques. Over the past decade, there has been a considerable advancement in 
the field of analytical glycoscience.12 This advancement, aided in part by the development of 










1.5.2. Analytical techniques 
Fluorescence spectroscopy was the initial analytical method of choice used to study CBP 
interactions. This technique involved screening a panel of CBPs such as lectins (coupled to a 
fluorescent probe such as rhodamine) with known binding specificities, against the glycan 
probes.4 However; due to poor data quantification and interpretation, the need of a label-free 
technique and the advent of new complex array platforms an alternative method was required.5  
Mass spectrometry (MS) and surface plasmon resonance (SPR) spectroscopy have since 
emerged as two prominent methods to tackle the above issues.4,5,12 More specifically,              
time-of-flight secondary ion mass spectrometry (ToF-SIMS) and surface plasmon resonance 
imaging (SPRi) are the two complementary techniques that are used to study the CBP events. 
ToF-SIMS is a mass spectrometry technique in which the surface interface (≈ 1.5-2.0 nm) is 
showered with a primary ion beam in order to generate detectable secondary ions. 
Quantification of these detected ions reveals the complex chemical composition of the 
glycoarrays, giving information pertaining to the chemical species surface distribution.5                       
In contrast, SPRi is a technique based on refractive index, in which the surface is irradiated with      
ρ-polarized light and the reflected light is detected. This allows for the observation of complex 
biomolecular interactions that occur at the surface interface, giving information related to the 
bioactivity of the glycoarray.5 In addition to this, both techniques have allowed for the surface 
chemistry of the arrayed glycans to be studied, revealing information pertaining to their 
neighbouring glycan probes and their molecular conformations. This is of the utmost 
importance as the surface chemistry plays a crucial role in both the bioavailability and function 
of the arrayed glycans; meaning that the quality of the printed array can now be quantified.           
In turn this allows for the fabrication and function of various glycoarrays to be optimized, 
greatly aiding in the actual application of the glycoarray.5 
With all of the above in mind a retrosynthetic analysis of the glycan-binding probe 11 from 
available starting materials was conducted, and a synthetic route towards 11 proposed.  
 





1.6. Retrosynthetic analysis 
As stated earlier, target bis-glucoside 11 was identified as the initial focus of this project.                         
A retrosynthetic analysis of 11 is presented below (Schemes 3 and 4), incorporating the one-pot 
bis-glucosylation reaction. Initially it reveals both penta-acetyl glucopyranose 3 and                            
N-acyl cysteine 12, to be the primary starting materials of 11, with the obvious challenge being 
whether 3 and 12 will undergo the serendipitously discovered bis-glucosylation reaction to 
afford the tethered BGC derivative 13. Deprotection of 13 would then afford target molecule 11, 
although it is recognized that selective de-O-acetylation without disrupting the α-glucosyl ester 





Scheme 3: Retrosynthesis of bis-glucoside 11 towards primary starting reagents’ 3 and 12. 
 
*IUPAC name: N-(4-azidobutanoyl)-L-cysteine (12)  
   
 





While penta-acetyl glucopyranose 3 was commercially available, N-acyl cysteine 12 was not and 
would need to be synthesized. A retrosynthetic analysis of 12 (Scheme 4) suggests L-cysteine 14 
and γ-butyrolactone 15 as precursors, both of which were available in house. The formation of 
12 would involve ring opening of the lactone 15 together with formation of a terminal bromide 
to afford 4-bromobutanoic acid 16. Bimolecular nucleophilic substitution (SN2) of the bromo 
acid 16 would then afford 4-azidobutanoic acid 17, which in turn would undergo a peptide bond 
coupling reaction with 14 to afford 12. Compounds 16 and 17 were both commercially available 
although 17 is considerably more expensive than 16 and the chemistry of the starting cyclic 




Scheme 4: Retrosynthesis of N-acyl cysteine 12 towards secondary starting reagents’ 14 and 15. 
 
 
Having settled on the use of penta-acetyl glucopyranose 3, L-cysteine 14 and lactone 15 in order 
to achieve the formation of bis-glucoside 11, a synthetic route was proposed together with 





*IUPAC name: dihydro-2(3H)-furanone (15)  
    
 





1.7. Proposed synthetic route 
The proposed synthetic route (Scheme 5) sought to achieve the formation of target                    
bis-glucoside 11 starting from the inexpensive lactone 15, using methodology from                          




Scheme 5: Reagents and conditions; i) 48 % HBr in H2O, conc. H2SO4, reflux; ii) NaN3, MeCN, reflux;                                           
iii) NHS, EDC.HCl, DCM, r.t.; iv) 14, NEt3, DMF, r.t.; v) 3, SnCl4, DCM, r.t. ; vi) NaOMe (0.1 M), MeOH, r.t.  
 
 
It is important to highlight six key features present in the proposed synthetic sequence.      
Firstly, the bromo acid 16 presented an affordable alternative to the starting material 15, in the 
event that access to 15 was limited. This is due to 15 being a border-controlled substance in 
certain countries as it is a prodrug of γ-hydroxybutanoate, a sedative used recreationally              
with alcohol.  





Secondly, the presence of an azido functionality in 17 will ultimately, allow for at least two 
possible strategies for attaching the glycan-binding probe 11 to a surface or other 
macromolecule, such as a Huisgen-type 1,3-dipolar cycloaddition reaction with an alkyne or 
reduction of the azide to an amine followed by peptide coupling as shown earlier in Figure 4, 
Page 10. Thirdly, formation of the succinimidyl ester 18 will make peptide coupling with                  
L-cysteine 14, in the subsequent step more likely due to increased electrophilicity at the acyl 
carbon site favouring the formation of N-acyl cysteine 12. Fourthly, the peptide coupling will be 
conducted in the absence of thiol protection as it is widely accepted that peptide bond 
formation, in which 14 is involved, occurs via a native chemical ligation (NCL) mechanism 
involving an S- to -N acyl transfer as shown in Scheme 6.18,19 Fifthly, there is a potential risk that 
the final deprotection step may result in cleavage of the α-glucosyl ester linkage, and this will 
have to be carefully investigated, including evaluating alternative protecting group strategies              
if necessary. Lastly, in the event that the bis-glucosylation reaction provides undesired               
results; the BGC scaffold or an alternative analogue bearing just one sugar unit will need to be 
prepared via alternative means. This alternative analogue would make use of the methyl ester 
derivative of S-glucosylcysteine 2, depicted earlier (Scheme 1, Page 4), as the formation of such 




Scheme 6: The proposed NCL mechanism for the reaction between 14 and 18 leading to the formation of 12 via 
14i. The key step involves an S- to -N acyl transfer from the sulfur atom (highlighted in red) to the nitrogen atom 
(highlighted in blue) of intermediate 14i.18,19 
 
*IUPAC name: 2,5-dioxopyrrolidin-1-yl 4-azidobutanoate 
    
 





A brief account of the key steps articulated above in the proposed synthesis is discussed       
below, together with recommendations for alternative approaches.  
  
1.7.1. The formation of S-glycosylcysteine derivatives from glycosyl acetates 
To date a handful of methods have been developed towards obtaining S-glycosylcysteine 
derivatives such as 19 depicted in Scheme 7.20–24 Arguably, the most used method to achieve 
this makes use of a suitable glycosyl donor and Lewis acid promotion. A typical reaction using 
the glycosyl acetate is promoted with an excess of either BF3.OEt2 or SnCl4.20,25 The excess 
promoter is required as the Lewis acid remains strongly associated to the eliminated anomeric 
acetate leading to Br∅nsted acid formation, in addition to being quenched with residual traces 
of water if present. Despite these set-backs this method allows for the direct conversion of               
commercially available, inexpensive starting material such as penta-acetyl glucopyranose 3 and                         
methyl N-acetyl-L-cysteinate 20 to S-glucosylcysteine derivative 19 in contrast to the more 
indirect route via the 1-thioglucopyranose 21 and 3-bromopropanoate 22 (Scheme 7), both of 
which are typically prepared via several steps.26,27 However, a major advantage of the latter 
approach is that it is non-moisture sensitive and produces higher reported yields.24 Nonetheless 
a Lewis acid approach involving glycosyl acetates would be pursued initially on the basis of the 





Scheme 7: Reagents and conditions: i) SnCl4, DCM, r.t., (lit. 65 %); ii) TBAHS, aq. NaHCO3 (0.6 M), EtOAc, 40 ºC.   
Note this reaction (ii) was performed with a differently protected analogue of 22 with a reported yield of 86 % 
being obtained for their target S-glucosylcysteine derivative).20,24        
*IUPAC names: methyl N-acetyl-S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-L-cysteinate (19) 
 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranose (21) 
  methyl (R)-2-acetamido-3-bromopropanoate (22) 
 
 





1.7.2 Peptide bond formation 
 
At the turn of the 19th century, Emil Fischer, proposed the use of acid chlorides in the synthesis 
of peptides. The success of this method in addition to the limited availability of complex 
peptides, spurred on the development of a several other peptide coupling strategies in the past 
century.28 Thus, in addition to acid chlorides; the two other prevalent strategies employed make 
use of carbodiimides and active ester chemistry. The choice of strategy employed is often 
dependent on the quantity of coupling reagent to be used, neighbouring groups                 
present, chemistry in either solution or solid phase, and whether automated or manual 
synthesis is used.28,29 The latter two variables were not relevant in this study, since the emphasis 
would be on step-wise, solution-based chemistry. 
 
1.7.2.1. Acid chlorides 
The inception of acid chlorides, by Fischer, in peptide chemistry was initially met with great 
interest. However, this slowly dwindled over time primarily due to the high reactivity of acid 
chlorides, making them susceptible to a range of possible side reactions including hydrolysis.      
In addition to this their preparation often involves the use of hazardous chlorinating                
reagents such as thionyl chloride, phthaloyl dichloride, and oxalyl chloride in excess.28,29 The use 
of excess reagent complicates matters even further, as its removal is usually achieved via 
evaporation under vacuum, meaning that frequent preparation of acid chlorides can lead to 














The carbodiimides are the reagents of choice in peptide coupling reactions. These 
carbodiimides contain two weakly basic nitrogen atoms that can initiate a reaction between the 
carbodiimide and carboxylic acid, such as N-acetyl-L-cysteine 4, leading to the formation of a 
highly reactive O-acylurea species (Scheme 8) such as 4i. This species can then undergo rapid 
aminolysis with an amine such as methyl L-serinate 23 to afford the desired peptide product 24. 
However, a possible side reaction is the irreversible rearrangement of the O-acylurea species 4i 
to the more stable N-acylurea species 25. This undesirable side reaction proceeds more rapidly 
in dimethylformamide than in dichloromethane. In order to circumvent this undesired result, 
additives bearing a triazole scaffold such as 1-hydroxybenzotriazole (HOBt) are often used in 
conjunction with the carbodiimide reagent. Firstly, these additives serve to protonate the O-acyl 
urea species, preventing an intramolecular attack from occurring and secondly, they drive the 
desired reaction forward via the formation of an in situ active ester. Two commonly employed 
carbodiimide reagents, are 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC.HCl) and N,N'-dicyclohexylcarbodiimide (DCC)  the former being  the reagent of choice as it 
overcomes the shortcomings of its predecessor DCC. This is as a result of DCC forming a urea 






Scheme 8: A hypothetical carbodiimide reaction between 4 and 23, promoted by DCC (containing weakly basic 
nitrogen atoms highlighted in blue) to afford the peptide product 24 and urea salt by-product (encircled in red) via 
the O-acylurea species 4i. The O-acylurea species 4i can also undergo an irreversible rearrangement to afford the                                         
undesired N-acylurea species 25.28,29 





1.7.2.3. Active esters 
Thus it is no surprise that the arrival of active esters to the field of peptide chemistry was met 
with great enthusiasm, as they addressed the drawbacks associated with acid chlorides and 
carbodiimides. Active esters are in fact mixed anhydrides, being stable enough to be         
isolated, yet just reactive enough to undergo only the desired nucleophilic acyl substitution 
reaction.28,29 They are usually prepared, under standard carbodiimide-ester conditions, from a 
carboxylic acid such as 4 and either a phenyl or hydroxamic alcohol. In the former approach the 
introduction of a p-nitrophenyl (pNO2), 2,4,5-trichlorophenyl (pCl)  or pentafluorophenyl (pF) 
group (Figure 5) primes the acyl carbon towards nucleophilic attack, due to the excessive 
electron-withdrawing nature of the substituted aromatic rings. However, the major limitation of 
phenyl active ester derivatives is the formation of a water insoluble by-product complicating the 
work-up. With regard to hydroxamic active esters (Figure 5) o-phthalimdo active esters were 
initially used, but they too formed a water insoluble by-product.28,29 The solution to this came in 
the form of succinimidyl active esters, as the N-hydroxysuccinimide (NHS) released during 
aminolysis is water soluble. Despite this advantage, NHS active esters are significantly less 




Figure 5: Hypothetical phenyl (top row) and hydroxamic (bottom row) active esters of 4.28,29 
 





It was hoped that if the preparation of glycan-binding probe 11, as outlined earlier                            
(Scheme 5, Page 15), was successful that the process could be repeated with biologically 
relevant sugar units other than glucopyranose. In addition to this, two other important variables 
that needed to be taken into account were the linker length and CBP-specificity to either one or 
both of the glucosyl units found in 11. The former factor is of the utmost importance as it plays 
a significant role during the recognition event, which can be hindered by the probe being in 
close proximity to the surface. With regards to the latter factor, it is unknown whether the 
targeted CBP will recognize and bind to the individual glucosyl units of 11, be unable                            
to distinguish the individual glucosyl units (multivalent presentation), or recognize the entire               
de-O-acetylated BGC scaffold as a single receptor, and this would remain to be established 
experimentally.30 
With the above two factors in mind, two additional glycan-binding probes designated as                                                  
bis-(N-acetylglucosaminyl)-L-cysteine (BAGC) and S-(glucosyl)-L-cysteinate (SGC), are shown 
alongside the BGC probe in Figure 6. Both of these probes are of significant interest, together, 
with the BGC probe as they would arm the glycobiologist with an effective molecular toolset 




Figure 6: Three potential components of a glycoarray conceptualized from the serendipitous discovery of BGC 1. 

























2.  Results and Discussion 
2.1. Preparation of N-(4-azidobutanoyl)-L-cysteine 
 
As outlined earlier (Scheme 5, Page 15), the preparation of key synthetic intermediate 12 was 
proposed via a four-step synthesis starting with γ-butyrolactone 15. The synthesis, as described 
below, was eventually achieved in six steps. 
The first step involved refluxing 15 with a solution of 48 % HBr in water and concentrated H2SO4 
for 15 h, and a single product was isolated as a yellow solid in a 72 % yield, whose m.p. of 32 ºC 
agreed with the reported literature value.13,31 The 1H NMR spectrum of the solid included a           
two-proton triplet at 3.48 ppm consistent with the presence of the alkyl bromide, confirming 
the formation of the bromo acid 16.  
The next step required the SN2 substitution of the bromo acid 16 with sodium azide in either 
acetonitrile or dimethylformamide at 85 ºC.14,15 Attempts in either solvent were, however, 
unsuccessful as in both cases the sodium azide remained visibly insoluble. This was confirmed 
by an IR-spectrum of the crude product isolated from the reaction conducted in 
dimethylformamide, which showed the absence of a diagnostic azide stretch at ≈ 2100 cm-1. 
Furthermore the 1H NMR spectrum of the crude product revealed that 16 had undergone 














In light of this result it seemed appropriate to attempt the formation of the azido acid 17 via an 
indirect route, involving conversion of the bromo acid 16 to the corresponding methyl ester 26 




Scheme 10: Reagents and conditions: i) 48 % HBr in H2O, conc. H2SO4, 0 °C for 1 h and then reflux for 14 h, 72 %;               
ii) conc. H2SO4 (cat.), MeOH, reflux, 3 h, 84 %; iii) NaN3, DMSO, 50 °C, 4 h, 48 %; iv) aq. NaOH (1.0 M), MeOH, 4 h, 
r.t., 65 %. 
 
 
The bromo acid 16 was therefore refluxed in methanol in the presence of a catalytic amount of 
H2SO4 for 3 h to give the methyl ester 26 which was isolated as a colourless, viscous liquid in 
good yield.32 This was confirmed, inter alia, by the 13C NMR spectrum of the viscous liquid which 
showed a one-carbon singlet at 51.8 ppm consistent with the presence of the methyl ester.  
The methyl ester 26 was then treated with a slight excess of sodium azide in dimethyl sulfoxide 
at 50 ºC for 4 h to form the 4-azidobutanoate 27 which was isolated as an off-yellow, viscous 
liquid.33 The 1H and 13C NMR data for the viscous liquid were in agreement with literature data 
for this compound.35 Furthermore the IR-spectrum showed a diagnostic azide stretch at             
2095 cm-1 consistent with the presence of the azide, confirming the formation of the alkyl azide. 
Although contamination with dimethyl sulfoxide was evident from the presence of a singlet 
resonating at δH 2.62 ppm, a pure product was eventually obtained in moderate yield when 
several cold aqueous washes were applied during the work-up. 
 
*IUPAC names: methyl 4-bromobutanoate (26) 
  methyl 4-azidobutanoate (27) 
 





The 1H NMR spectra (Figure 7) of isolated compounds 16, 26 and 27 are compared to highlight 
the incorporation of the methyl ester and shielding effect of the azide relative to bromine on 
the terminal methylene group. 
 
 
Figure 7: A comparison of the 1H NMR spectra (1.75 - 3.70 ppm) for isolated compounds 16, 26 and 27. 
 
Hydrolysis of the 4-azidobutanoate 27 was then accomplished by using an aqueous NaOH 
solution and a minimal amount of methanol, which was required together with vigorous stirring 
in order to obtain a homogeneous solution.34 After 4 h the azido acid 17 was isolated in good 
yield as an off-yellow, viscous liquid. This was confirmed by the 1H NMR spectrum of the viscous 
liquid which showed the disappearance of the three-proton singlet at 3.67 ppm for the methyl 
ester of 27, consistent with the formation of the carboxylic acid. 
With the desired azido acid 17 now in hand, the proposed synthesis of N-acyl cysteine 12 could 
be resumed, with the next step involving esterification with NHS. 





The azido acid 17 was thus treated with NHS in the presence of EDC.HCl overnight, yielding a 
single, less polar product which was isolated as a colourless oil in an 82 % yield.14,36 The 1H NMR 
spectrum of the oil showed a four-proton singlet at 2.82 ppm consistent with the presence of 
the isochronous protons of the succinimidyl group, confirming the formation of the                     
succinimidyl ester 18. Interestingly a comparison of the 13C NMR spectra (Figure 8) obtained            
for isolated compounds 17 and 18, showed a noticeable shielding of C-1 from 179.1 ppm to 




Figure 8: A comparison of the 13C NMR spectra (20.0 - 180.0 ppm) for isolated compounds 17 and 18. The region                          
(80.0 - 165.0 ppm) has been omitted for clarity.  
  
 
The succinimidyl ester 18 was then reacted with L-cysteine hydrochloride 14 under basic 
conditions in dimethylformamide.15 After 14 h, TLC showed the disappearance of 18; together 
with the presence of a highly polar product, having a similar streaking pattern to 14 and             
giving the same colour as N-acetyl-L-cysteine 4 upon heating with a ninhydrin solution.                               
After an extensive aqueous work-up the highly polar product was isolated as an off-yellow oil in 
a 45 % crude yield  





The 1H NMR spectrum of the oil (Figure 9) showed the presence of a one-proton doublet at     
6.67 ppm and a one-proton triplet at 1.49 ppm, corresponding to an amide proton and thiol 
proton respectively, confirming the formation of target N-acyl cysteine 12. 
 
 
Figure 9: The 1H NMR spectrum of the crude reaction product containing compound 12. Only the region                      
(1.40 - 6.70 ppm) has been shown due to the presence of some contamination.  
 
 
At this point the possibility of bis-glucosylation of the partially purified sample of 12 was 
investigated by treating it with penta-acetyl glucopyranose 3 and SnCl4 in dry dichloromethane.7 
The reaction did not go to completion; however, two more polar products had formed, with the 
least polar of the two being isolated as a colourless oil after careful column chromatography. 
This product was identified as the tetra-acetyl glucopyranose 28 according to the 1H NMR 
spectrum of the oil,37 indicating that hydrolysis of 3 had taken place, presumably via an 
oxocarbenium ion OI or 1,2-acetoxonium ion AI as shown in Scheme 11.  
 





Scheme 11: The hydrolysis of penta-acetyl glucopyranose 3 (not shown here) in the presence of SnCl4 via OI or AI, 
to afford the undesired product 28. 
*IUPAC name: 2,3,4,6-tetra-O-acetyl-D-glucopyranose (28) 
 





This outcome prompted a detailed re-examination of the reaction conditions required for the 
originally reported bis-glucosylation reaction. 
 
2.2. Reproducing the bis-glucosylation of N-acetyl-L-cysteine 
 
In order to investigate in detail the optimal reaction conditions for the bis-glucosylation of                
N-acetyl-L-cysteine 4 with penta-acetyl glucopyranose 3, these reactants were initially 
combined in dry dichloromethane and the promotor SnCl4 added according to the reported 
literature procedure.7 After 3 h as judged by TLC, two polar products had formed and a 
significant amount of starting material 3 still remained. In addition, a small amount of 4 was 
also visibly present in the reaction vessel, and the reaction also appeared not to progress any 
further after 3 h. Both of the products and the starting material 3 were isolated as colourless 
oils after extensive column chromatography. The product presumed to be the starting material 3 
was shown by 1H NMR (Figure 10) and comparison with literature data38 to be a mixture of 3, its             
α-anomer 29 and the glucosyl chloride 30 in a ratio of 1:6:8 as judged from integration of their 
respective anomeric protons. Also shown (Figure 10) is the relatively deshielded three-proton 




Figure 10: The 1H NMR spectrum (1.95 - 6.35 ppm) of the presumed starting material 3. Anomeric protons for 
compounds 3, 29 and 30 are designated by numbered peaks in the region (5.65 - 6.35 ppm). 
*IUPAC name: 1,2,3,4,6-penta-O-acetyl-α-D-glucopyranose (29)                                                                                                                                         
v2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl chloride (30) 





These observations are consistent with work conducted by Konstantinović et al. in which             
they observed the formation of the glucosyl chloride 30 as a by-product when treating                                
3 with various alkyl alcohols in the presence of SnCl4 in dry dichloromethane.39 Tetra-acetyl 
glucopyranose 28 was again identified as a minor product, and the most polar product 
identified as the S-glucosylcysteine derivative 2 according to their respective 1H NMR spectra.7,37 
Similar results were obtained on repeating this reaction on a small scale (300-500 mg) over 
prolonged reaction times or at temperatures up to 35 ºC, and with rigorous exclusion of water 
by using dry solvents and activated molecular sieves. The use of alternative Lewis acids was also 
investigated, with trimethylsilyl trifluoromethanesulfonate (TMSOTf) and BF3.OEt2 providing a 
similar product distribution, despite no visible presence of 4 in the reaction vessel after 3 h, 
unlike the case when SnCl4 was used. This time, however, the 1H NMR spectrum of the product 
contained signals at 3.00-3.20 ppm consistent with the diastereotopic methylene protons in 
cysteine. Despite this the 1H NMR spectra lacked the required diagnostic signals correlating to 
BGC 1. In a final attempt at forming 1, a SnCl4 solution (1.0 M in DCM) was used but the reaction 
mixture gave the same TLC profile after 3 h. However, one of the isolated products contained     
all the diagnostic signals expected for 1, confirming its formation in a 12 % crude yield.                  
The 1H NMR spectrum of this partially purified sample of 1 can be found in the Appendix             
(Page 105) of this dissertation. Further purification of 1 was not attempted in light of its 
potential degradation.  
The exact mechanism leading to the formation of 1 is not known. However, based on the 
configurational outcomes of 1 and 2, a postulated mechanism leading to the formation of 1 is 
put forth below in Scheme 12. It must be mentioned that the postulated mechanism bears an 
intriguing resemblance to some of the key mechanistic steps catalyzed by glycosyltransferases 
and glycosidases.40 
 







Scheme 12: A postulated mechanism for the formation of BGC 1. During the key TS, the α-glucosyl ester linkage 
(highlighted in red) is formed and the initial β-thioglucoside linkage (highlighted in blue) is broken leading to 3ii.   
 
Mechanistically the formation of 1 is envisioned to proceed via oxocarbenium ion OI, prior to an 
intramolecular attack at C-1 by the acetyl oxygen to afford intermediate AI. This is then followed 
by attack of the nucleophilic sulfur of 4 at the anomeric position of AI, to afford 3i having a            
β-configuration. The carboxylic acid of 3i is then positioned to displace the primed anomeric 
sulfur via a cyclic 6-membered-ring transition state (TS), with inversion of configuration, leading 
to formation of the α-acylglucoside 3ii. The α-acylglucoside 3ii then undergoes process A once 
more to afford 1.  





From these results, it appeared that the bis-glucosylation reaction was being hindered due to 
the anomerization of 3, poor solubility of 4 (when using SnCl4) and possible residual traces of 
water. It was also possible that the poor solubility of 3 was preventing the sulfhydryl group from 
intercepting the AI intermediate, effectively halting the progress of the desired reaction. In an 
effort to investigate this, a series of additional experiments were set up, where it was hoped 
that the yield of 1 could be optimized. These experiments involved altering the order in which 
the reactants were combined, decreasing the rate at which the promotor SnCl4 was added, 
increasing the equivalents of 3 used, and using dichloromethane that had been distilled and 
stored over 3 Å molecular sieves for 2 days.41 Unfortunately they were all met with limited 
success, as according to TLC the dominating products formed were the glucosyl derivatives 2, 28 
and 30 once again.  
 
With failure to improve on the efficiency of the one-pot formation of 1, the attention now 
turned to the selective synthesis of a SGC probe to study carbohydrate-binding phenomena, and 
as a potential precursor to the step-wise preparation of the bis-glucosylated analogue either 
chemically or enzymatically, via a suitable glycosyltransferase, as depicted in Scheme 13.                
This would firstly require the preparation of an alternative glycosyl acceptor (GA).   











Scheme 13: A revised concept towards the synthesis of a SGC probe via an alternative GA and its potential 
extension towards the BGC analogue. 










2.3.1. Route via an azido acid and methyl L-cysteinate 
 
The first objective in this phase of the work was to prepare adequate quantities of                        
N-acyl cysteine 12 or its analogues. The first synthesis of 12, reported earlier, had led                        
to an impure product in a rather low yield. An alternative was therefore considered                                
in preparing the azido-GA 31 starting with readily available 6-aminohexanoic acid 32 as outlined 




Scheme 14: Reagents and conditions: i) K2CO3, CuSO4.5H2O, 33, MeOH, 16 h, r.t., 35 %; ii) NHS, EDC.HCl, DCM,                   
0 ºC - r.t., overnight, 75 %; iii) methyl L-cysteinate.HCl 36, NEt3, DCM, 0 ºC - r.t. over 1 h then r.t. for 13 h, (yield not 
determined due to contamination). 
 
It was envisaged that the use of the diazotransfer reagent, 1H-imidazole-1-sulfonyl azide 
hydrochloride 33 would allow for the direct conversion of the amino acid 32 to 6-azidohexanoic 
acid 34, in a more efficient route than the four-step route to the azido acid 17 as                    
described earlier. Often such conversions involve the use of unstable and explosive 
trifluoromethanesulfonyl azide (TfN3) as the diazotransfer reagent whereas the sulfonyl azide 33 
is a safer alternative, prepared from inexpensive and readily available materials.44–46 
 
*IUPAC name: methyl N-(6-azidohexanoyl)-L-cysteinate (31) 





Secondly, methyl L-cysteinate hydrochloride 36 was chosen instead of L-cysteine 14. It was 
hoped that the presence of the methyl ester would make isolation of the azido-GA 31 less 
troublesome and circumvent the need to use dimethylformamide due to improved solubility. 
In order to form the sulfonyl azide 33, sulfuryl chloride 37 was initially allowed to react with 
sodium azide in acetonitrile overnight, before the addition of imidazole.42 After 3 h the product 
was isolated as a white crystalline solid in a 72 % yield, whose m.p. of 100-101 ºC agreed with 
the reported literature value.42 Furthermore the IR-spectrum showed a diagnostic azide stretch 
at 2169 cm-1 consistent with the presence of the azide, confirming the formation of the sulfonyl 
azide 33, depicted in Scheme 15. With the bench-stable diazotransfer reagent at hand, the 
desired diazotransfer reaction could be attempted. 
 
 
   
Scheme 15: Reagents and conditions; i) NaN3, MeCN, 0 ºC - r.t., overnight; ii) imidazole, 0 ºC - r.t. over 30 min           











The amino acid 32 was then treated with 33 under basic conditions in the presence of                        
a catalytic amount of CuSO4.5H2O in methanol for 16 h, to form the desired azido acid                         
34 which was isolated as an off-yellow oil in low yield.42,43 This was confirmed, inter alia, by the                         
IR-spectrum of the oil which showed a diagnostic azide stretch at 2090 cm-1 consistent with the 
presence of the alkyl azide. 
The azido acid 34 was then subjected to the same reaction conditions that led to the formation 
of the four-carbon succinimidyl ester 18, with the desired six-carbon succinimidyl ester 35 being 
isolated as an off-yellow oil in good yield.14,36 This was confirmed by the 1H NMR spectrum of 
the oil which showed a four-proton singlet at 2.82 ppm consistent with the presence of the 
isochronous protons of the succinimidyl group.  
 
*IUPAC name: 2,5-dioxopyrrolidin-1-yl 6-azidohexanoate (35) 





Unfortunately attempts at coupling the succinimidyl ester 35 to the amine 36 under basic 
conditions in dry dichloromethane met with limited success, with TLC revealing the formation of 
several products in the reaction.47 This was despite 36 having improved solubility in 
dichloromethane as was desired. Nonetheless the presumed product was isolated as a crude oil 
after extensive column chromatography. The 1H NMR spectrum of the oil showed the 
appearance of signals analogous to those seen for N-acyl cysteine 12, yet consistent with the 
azido-GA 31 having two additional saturated carbons. However, the 1H NMR spectrum of the oil 
also revealed the presence of several impurities and attempts to purify this mixture further only 
led to a substantial loss of product, concomitant with impurities still present.  
The lack of selectivity in this reaction could be due to a combination of the thiol group of 31 
undergoing oxidation to the disulfide and or that S- to N-acyl transfer was not going to 
completion, leading to the potential formation of undesired by-products 38 and 39, depicted in 
Figure 11. The possibility of oxidation is supported by work conducted by Dumitriu et al. 
involving treatment of 36 with a phenothiazine succinimidyl ester derivative under the exact 
same reaction conditions.48 However, in their case they were able to isolate both the 
monomeric and dimerized product in yields of 43 % and 53 % respectively.48 
 
 








These observations suggested the need for an alternative route towards the envisioned GA 
using an S-protected derivative of cysteine and a succinimidyl ester with a terminal group other 
than the azide. 





2.3.2. Alternative synthetic route involving S-protected cysteine derivatives 
 
After consulting the literature two alternative routes (Route A and Route B) towards obtaining 
the N-Boc-GA 40 (Scheme 16) were identified, involving protection of the thiol as the tert-butyl 


















Scheme 16: Illustrates two indirect routes (Route A and Route B) and one direct route (Route C) towards obtaining 




In addition, the low yields encountered in the key azidation step in the earlier sequences led to 
the incorporation of an N-Boc protecting group in the proposed synthetic route. Although this 
would preclude the use of azide-alkyne “click” chemistry in the subsequent attachment to solid 
supports, removal of the N-Boc group would allow for peptide-coupling, as illustrated earlier 
(Figure 4, Page 10) in the formation of glycoarrays or similar applications 
The first objective was therefore to prepare the succinimidyl N-Boc analogue 45, shown below 
(Scheme 17), of the earlier succinimidyl azide target 35 which proved successful.55,56  
 
 
*IUPAC names: methyl N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-L-cysteinate (40) 
 2,5-dioxopyrrolidin-1-yl 6-((tert-butoxycarbonyl)amino)hexanoate (45) 







Scheme 17: Reagents and conditions; i) Boc2O, NEt3, MeOH, reflux, 24 h, 88 %; ii) NHS, EDC.HCl, DCM, 0 ºC - r.t.,  




To this end, the amino acid 32 was treated with Boc-anhydride and refluxed in methanol under 
basic conditions for 24 h, to give the N-Boc acid 46 as a single less polar product which was 
isolated as a white solid in high yield.55 This was confirmed by the 1H NMR spectrum of the solid 
which showed the appearance of a nine-proton singlet at 1.43 ppm consistent with the 
formation of the carbamate.  
Conversion of the N-Boc acid 46 to the succinimidyl ester 45 proceeded smoothly in the                  
same manner as described earlier for its azido acid counterparts, with the desired product being 
isolated as a white solid in high yield.14,36 This was confirmed by the 1H NMR (Figure 12)           








Figure 12: The 1H NMR spectrum (1.35 - 4.75 ppm) of the succinimidyl ester 45.  
 
With the succinimidyl ester 45 now in hand the preparation of the N-Boc-GA 40 via Route A     
was pursued. 
*IUPAC name: 6-((tert-butoxycarbonyl)amino)hexanoic acid (46) 





2.3.2.1. Route A: S-tert-butyl protection 
 
Route A was selected above that of Route B initially as the removal of an S-benzyl protecting 
group via hydrogenation is known to be problematic due to sulfur poisoning of the catalyst. 
Therefore, the amine 36 was allowed to react with tert-butanol in trifluoroacetic acid (TFA)             
for 18 h.49 After the removal of excess TFA a white wax-like solid was isolated in a 63 % yield.               
The 1H NMR spectrum of the wax showed the presence of a nine-proton singlet at 1.33 ppm 
consistent with the tert-butyl thiol, confirming the formation of the tert-butyl thioether 41.            
The presence of the TFA counterion was evident from the three-fluorine singlet at -75.7 ppm in 
the 19F NMR spectrum. 
The succinimidyl ester 45 was then reacted with a slight excess of the tert-butyl thioether 41 
under basic conditions in dichloromethane.47 After 24 h TLC showed the disappearance of 45 
together with the formation of a slightly less polar product which was isolated as a colourless oil 
in a 64 % yield. The 1H NMR spectrum of the oil showed a characteristic one-proton doublet at 
6.23 ppm consistent with the presence of the amide bond, confirming the formation of the 
protected N-acyl cysteine 42, depicted in Scheme 18. The formation of 42 was further 
corroborated by the 13C NMR spectrum having 15 signals, which correlated to the required 19 
carbon atoms taking into account signals which coincide due to symmetry, and the detection in 





Scheme 18: Reagents and conditions; i) TFA, tBuOH, r.t., 18 h, 63 %; ii) 45, NEt3, DCM, 0 ºC for 1 h then r.t. for 23 h,               
64 %.  
 
 
     
An attempt was then made to deprotect the thioether via disulfide formation, using 
dimethyl(methylthio)sulfonium triflate (DMTST) followed by reduction.  
*IUPAC names: methyl S-(tert-butyl)-L-cysteinate trifluoroacetate (41) 
 methyl N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-S-(tert-butyl)-L-cysteinate (42) 





Unfortunately at the time the reagents required to prepare DMTST were not at hand.50 In light 
of this an alternative to DMTST was prepared by treating dimethyl sulfide with triflic anhydride 
(Tf2O) in dichloromethane to afford an equivalent reagent 47 (Scheme 19) as a stock solution 
(1.0 M in DCM).57,58 The protected N-acyl cysteine 42 was then treated with the freshly 
prepared solution of 47 under basic conditions in tetrahydrofuran for 6 h followed by addition 
of a small amount of water and tributylphosphine in order to reduce the presumed disulfide 
intermediate 42i, depicted in Scheme 19.50 Unfortunately after a further 3 h TLC showed the 
presence of only starting material 42, and this was confirmed by 1H NMR of the isolated 
product. The failure of this reaction was not investigated further, although a potential reason is 
that the thiolating reagent 47 may have been quenched by trace amounts of water. From TLC it 
was evident that a significant amount of starting material 42 was still present after 6 h. 
 
 
   
 
 
Scheme 19: A proposed mechanism for the conversion of the protected N-acyl cysteine 42 to the desired N-Boc-GA 
40, via the intermediate disulfide 42i. The key steps involve S-C bond cleavage (highlighted in blue) and S-S bond 











Further attempts at this reaction were not made on the basis of the postulated side reactions 
taking place, the appropriate reagents not being at hand at the time and the strong residual 
odour left on the rotary evaporator, despite the reaction being done on a small scale. In light of 
this Route A was abandoned and Route B was pursued instead. 





*IUPAC names: methyl S-benzyl-L-cysteinate hydrochloride (43) 
 methyl S-benzyl-N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-L-cysteinate (44) 
2.3.2.2. Route B: S-benzyl protection 
 
As an alternative, Route B involving preparation of a benzyl thioether, was then investigated.  
Therefore, the amine 14 was allowed to react with benzyl bromide under basic conditions in 
ethanol for 1 h.51 Acidification of the reaction mixture in ice afforded a white crystalline solid in 
a 71 % yield, whose m.p. of 201-204 ºC agreed with the reported literature value for S-benzyl-L-
cysteine hydrochloride 48.51 Furthermore both the 1H and 13C NMR data for the solid were in 
agreement with literature data for this compound, confirming the formation of 48.  
The benzyl thioether 48 was then treated with a methanolic hydrogen chloride solution, 
generated in situ from the addition of excess acetyl chloride to methanol at 0  ºC, and left to stir 
for 15 h.52 After standard work-up a white crystalline solid was isolated in a 67 % yield.                 
The 1H NMR spectrum of the solid included a three-proton singlet at 3.74 ppm consistent with 
the presence of the methyl ester, confirming the formation of the S-benzylcysteine methyl ester 







Scheme 20: Reagents and conditions; i) aq. NaOH (2.0 M), BnBr, EtOH, r.t., 1 h, 71 %; ii) AcCl, MeOH, 0 ºC for 1 h 





The ester 43 was then combined with the succinimidyl ester 45 under basic conditions in 
dichloromethane and gave, after 24 h a less polar, UV-active product which was isolated as a 
white solid in a 72 % yield.47 The 1H NMR spectrum, depicted below (Figure 13) showed a 
characteristic one-proton doublet at 6.12 ppm consistent with the presence of the amide bond, 
confirming the formation of the protected N-acyl cysteine 44. The formation of 42 was further 
corroborated by the 13C NMR spectrum having 18 signals, which correlated to the required 22 
carbon atoms taking into account signals which coincide due to symmetry, and the detection in 
the HRMS spectrum of a molecular ion [M + H]+ of the required m/z 439.2278. 






















The next step involved the removal of the S-benzyl protecting group of 44. Arguably the most 
used method to achieve this makes use of the reductive power of sodium in liquid          
ammonia, developed by du Vigneaud et al. in the 1930’s.53,54 However, with this not being 
readily available, catalytic hydrogenation of the benzyl group was attempted as the           
alternative, although reports of the limitations of this approach due to poisoning of the                 
Pd catalyst by sulfur were noted.59 
However, when the protected N-acyl cysteine 44 in the presence of Pd/C (10 %, 10.0 eq.) in dry 
methanol, was treated under a balloon of H2 gas, there was no evidence for conversion even 
after 48 h, and only starting material 44 was recovered. The recovered starting material 44 was 
therefore subjected to catalytic phase transfer hydrogenation (CPTH) involving the use of  a zinc 
dust as a catalyst and ammonium formate in dry methanol, but this also failed to remove the 
benzyl group, even after extending the duration of the reaction and adding excess ammonium 
formate.60,61 It was thus clear that the use of either the S-benzyl or S-tert-butyl protecting 
groups was not appropriate. Use of alternative thiol protecting groups, such as p-nitrobenzyl,                  
p-methoxybenzyl and triphenylmethyl were not therefore not considered as they would be 
associated with similar limitations.62 





This led to a return at attempting the preparation of 40 via Route C, depicted earlier         
(Scheme 16, Page 35), utilizing the amine 36 and taking into account the possibility of reducing 
any disulfide formed in the process due to the presence of the free thiol group. 
 
2.3.3. Route via an N-Boc acid and methyl L-cysteinate 
 
In order to prepare the N-Boc-GA 40, the amine 36 was treated with the succinimidyl ester 45 
under basic conditions in a mixture of acetonitrile and water (1:1) instead of dichloromethane 
in an attempt to deal with the poor solubility of 36 during the initial stages of the reaction.63 
After 18 h, two products with similar polarity were isolated as white solids after repeated 
column chromatography. The 1H NMR spectra (Figure 14) of both solids are compared and show 







Figure 14: A comparison of the 1H NMR spectra (1.25 - 6.75 ppm) of the presumed N-acyl and S-acyl products. 
Despite sharing broad similarities a key difference occurs in the region (3.00 - 3.20 ppm, encircled in blue).                            
A zoomed in section of this region is also shown in the top left corner. 





In addition the solids had different melting points yet the same molecular ions [M + H]+ of                 
m/z 349.1798 and m/z 349.1783, the difference being accepted within the given margin of 
error, in their respective HRMS spectra; suggesting that they could be the isomeric N-acyl 




Scheme 21: Reagents and conditions; i) NEt3, H2O:MeCN (1:1), 0 ºC for 1 h then r.t. for 17 h, (40, 76 %) and              




This was confirmed by 2D NMR (HSQC, COSY). From their respective COSY spectra the less polar 
product was identified as the desired N-acyl product 40, with the more polar product being 
identified as the intermediate S-acyl product 49. The key evidence was the signal in the COSY 
spectrum of 40, shown below (Figure 15), corresponding to the homonuclear coupling between 
the diastereotopic protons (H-3) and the thiol proton (S-H). The S-acyl derivative 49 was isolated 
as the minor product and attempts were made to convert it to the target molecule 40 via                    
S- to N-acyl transfer as illustrated earlier (Scheme 6, Page 16) by stirring 49 in a solution of dry 
dichloromethane containing triethylamine for several hours. Unfortunately no conversion of 49 
to 40 was observed. This could indicate that an inter- rather than intra-molecular S- to N-acyl 
transfer takes place in going from 49 to 40 or that the steric bulk of the acyl group hinders the 
formation of the intermolecular 5-membered-ring transition state as suggested by                            
El-Gendy et al.64 However this was not explored any further as a substantial amount of 40                
(≈ 5.00 g) had been prepared at the time and the project focus pertained to the synthesis of          
the SGC probe.  
*IUPAC name: methyl S-(6-((tert-butoxycarbonyl)amino)hexanoyl)-L-cysteinate (49) 









Figure 15: The COSY NMR spectrum (1.25 - 6.50 ppm) of the N-acyl product 40. The key homonuclear couplings 
(encircled in blue) have been assigned. 
  
With the N-Boc-GA 40 now in hand the mono-glucosylation with penta-acetyl glucopyranose 3 
could be attempted, under conditions similar to that used in the attempted formation of BGC 1. 
Unfortunately attempts at coupling 40 with 3 using SnCl4 or BF3.OEt2 as promoters met with 
limited success once again, with a significant amount of unreacted 3 and 40 detected by TLC. 
Increasing the quantity of the Lewis acid or use of extended reaction times did not                   
improve matters.  
In light of this a decision was made to identify ideal reaction conditions leading to                         
S-glycosylcysteine formation, under Lewis acid promotion, rather than to waste further               
precious material. 





2.4. Glycosylation of cysteine derivatives with glycosyl acetates 
  
The target S-glycosylcysteine derivatives selected for this study were; the 2-O-acetyl derivatives 






Figure 16: The target 2-O-acetyl (left) and 2-acetamido (right) S-glycosylcysteine derivatives. 
 
They were chosen with a view to investigate the influence of the free carboxylic acid on the 
formation and stability of the β-thioglycoside, and to incorporate a biologically relevant sugar 
unit such as the 2-acetamido sugar. Targets 2 and 19 were prepared using the methods 
established by Nokwequ et al., although no attempts were made to optimize the yields obtained 
thus far.7,20 Initial attempts at preparing 50 by analogous routes were unsuccessful, leading to 
development of a new strategy. The detailed report of this synthesis follows.  
Mono-glucosylation of N-acetyl-L-cysteine 4 with penta-acetyl glucopyranose 3 in dry 
dichloromethane using SnCl4 was performed first, according to the literature procedure to form 
the desired product 2 which was isolated as a white foam in low yield (Scheme 22) after 
extensive column chromatography. The low yield obtained is consistent with the work of 
Nokwequ et al. where the instability of S-glycosylcysteine derivatives having a free carboxylic 













Scheme 22: Reagents and conditions; i) SnCl4, DCM, r.t., 3 h, (2, 34 %) or (19, 64 %). 
 
*IUPAC names: N-acetyl-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-L-cysteine (50) 
  methyl N-acetyl-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucospyranosyl)-L-cysteinate (51) 





When the above procedure was repeated with methyl N-acetyl-L-cysteinate 20 there was 
noticeable absence of any hydrolyzed tetra-acetyl glucopyranose 28 and only a minimal amount 
of unreacted starting material 3 after 3 h. The polar product was isolated as a white solid in a   
64 % yield and the 1H NMR spectrum for the solid was in agreement with literature data for         
this compound, confirming the formation of 19 shown above in Scheme 22.7,20,23 It was thus 
confirmed that the methyl ester allowed for a more selective reaction, made the isolation of the 
product less troublesome and that the presence of a carboxylic acid in the reaction plays a                
role in facilitating the formation of 28 under Lewis acid promoted conditions. The possible 
interaction of the carboxylic acid with SnCl4 warrants further investigation.  
Unfortunately attempts at repeating the mono-glycosylation of 4 with the 2-acetamido 
glucopyranose 52 were unsuccessful. However, a single product was isolated as an amber oil in 
a low yield of 11 % and identified by 1H NMR and comparison with literature data as the 
oxazoline 53.65 The low yield obtained is attributed to the poor solubility of the reactants and 








   
Scheme 23: The mechanism for the formation of 53 from 52.65 The regeneration of the catalyst is supported by 
the work of Srivastava who performed the same conversion using only a catalytic amount of SnCl4.66 
 
*IUPAC names: 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranose (52) 
 2-methyl-(3,4,6-tri-O-acetyl-1,2-dideoxy-α-D-glucopyrano)-[2,1-d]-2-oxazoline (53) 





Oxazoline 53 is a potential glycosyl donor in its own right, but it was apparent from the reaction 
outcome that it was not activated by SnCl4. To verify this, additional oxazoline 53 was prepared 
in a simple two-step process by first acetylating 2-acetamido-2-deoxy-D-glucopyranose 54 with 
an excess of acetic anhydride in pyridine to afford an anomeric mixture of 52 and its α-anomer 
55 in a combined yield of 91 % and 9:1 ratio (α:β). The mixture of anomeric acetates were then 
refluxed in the presence of excess TMSOTf to yield the oxazoline 53 in a 76 % yield.67 Treatment 
of 53 with 4 in the presence of SnCl4 gave the same result as before (no reaction) confirming 




Scheme 24: The attempted conversion of the 2-acetamido glucopyranose 52 and oxazoline 53 to the desired           
S-glycosylcysteine derivative 50, under the reaction conditions; i) 4, SnCl4, DCM, r.t., 3-24 h. 
 
Due to the results illustrated (Scheme 24) a revised approach was considered, using a                     
2-azido glycosyl derivative as a glycosyl donor. It was thus decided to attempt formation of the    
S-glycosylcysteine derivative 56 using the 2-azido glucopyranose 57 which could be readily 









Scheme 25: Reagents and conditions; i) K2CO3, CuSO4.5H2O, 33, MeOH, r.t., 3 h; ii) Ac2O, pyridine, 24 h, r.t., 60 % 
over two steps; iii) SnCl4, DCM, r.t., 3 h; iv) BF3.OEt3, DCM, 0 ºC for 1 h then r.t. for 23 h. 
*IUPAC names: methyl N-acetyl-S-(2-azido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-L-cysteinate (56) 
 2-azido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranose (57) 
 2-amino-2-deoxy-D-glucopyranose hydrochloride (58) 
    





Briefly, 58 was reacted with the sulfonyl azide 33 under typical diazotransfer conditions as 
described before and after 2 h a distinct colour change indicated the formation of intermediate 
59 shown above in Scheme 25.42 Co-evaporation of residual solvent from the reaction mixture 
with toluene was followed by the addition of excess acetic anhydride and pyridine to the crude 
residue containg 59 (not isolated). After 24 h a single less polar product was isolated as a white 
crystalline solid in good yield after standard work-up. The 1H and 13C NMR data for the solid 
were in agreement with literature data for this compound, confirming the formation of the         
2-azido glucopyranose 57.69,70 This was further corroborated by the IR-spectrum of the solid 
showing a characteristic azido band at 2113 cm-1. Unfortunately attempts at converting 57 to 56 
with either SnCl4 or BF3.OEt2 were unsuccessful as TLC revealed no product formation, and other 
Lewis acids were not considered at this time. 
At this point it had become evident that the glycosylation of cysteine derivatives with glycosyl 
acetates under Lewis acidic conditions were giving undesired and or ambiguous results. It must 
be noted that glycosyl acetates are not regarded as the best glycosyl donors, but were explored 
here in order to follow up on the original work: it is quite possible that alternative glycosyl 
donors, such as glycosylimidates, halides, sulfides, etc could be more effective in combination 
with appropriate promotors,71,72 but a decision was made to rather pursue the synthesis of the 
desired SGC probe via a nucleophilic glycosyl thiol and a cysteine precursor with a suitable 









*IUPAC name: 2-azido-2-deoxy-β-D-glucopyranose (59) 
   





2.5. Alternative synthesis of the SGC and SAGC probes  
 
As was highlighted earlier (Scheme 7, Page 17), an alternative approach to making                                 
S-glycosylcysteine derivatives involves a straightforward SN2 substitution in which the anomeric 
thiol of the desired sugar displaces an appropriate leaving group present on the electrophilic 
substrate. It was hoped that this alteration in strategy would circumvent any of the undesired 
reactions from taking place that had been plaguing the anomeric sites of both 3 and 52, as was 
discussed in detail earlier. 
This alteration in strategy paid dividends in the end and was extended to the successful 
synthesis of the desired SGC probe via a convergent synthesis. In addition to this, repetition of 
this approach with the 2-acetamido sugar derivative, pleasingly, also led to the successful 
synthesis of an S-(N-acetylglucosaminyl)-L-cysteinate (SAGC) probe. A detailed account of this 
synthesis follows. 
 
2.5.1. Glycosylation of a masked cysteine derivative with 1-thioglucopyranose  
 
In order to implement this alternative strategy, 1-thioglucopyranose 21 and 3-iodopropanoate 
60 were identified as key synthetic intermediates, to allow for preparation of S-glucosylcysteine 
derivative 61 as depicted in Scheme 26.24,27 
   
 
 
Scheme 26: The revised synthetic approach towards S-glucosylcysteine derivative 61 based on literature.  
 
Compounds 21 and 60 were both successfully prepared according to literature procedures and 
coupled to give 61 in good yield. The detailed report of this synthesis follows, starting with the 
preparation of 60 as outlined below in Scheme 27.73,74  
*IUPAC names: methyl (R)-2-((tert-butoxycarbonyl)amino)-3-iodopropanoate (60) 
  methyl N-(tert-butoxycarbonyl)-S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-L-cysteinate (61) 
    










Scheme 27: Reagents and conditions: i) aq. NaHCO3 (2.3 M), Boc2O, THF, 0 ºC - r.t. over 1 h then r.t. for 6 h, 90 %;      
ii) I2, PPh3, imidazole, DCM, 0 ºC for 2 h then 0 ºC - r.t. over 4 h, 78 %. 
 
The first step involved treating the amine 23 with Boc-anhydride in methanol under mild                  
basic conditions for 6 h to form the N-Boc protected alcohol 62 which was isolated as a 
colourless oil in high yield.73 This was confirmed by the 1H NMR spectrum of the oil which 
showed a nine-proton singlet at 1.43 ppm, consistent with the formation of the carbamate. 
The N-Boc protected alcohol 62 was then subjected to the Appel reaction to form the                        
3-iodopropionate 60 which was isolated as a white solid in good yield, despite a lengthy              
work-up required to remove the triphenylphosphine oxide.74 The formation of 60 was 
confirmed by 13C NMR (Figure 17) which showed a diagnostic one-carbon singlet at 7.9 ppm, 




Figure 17: The 13C NMR spectrum (5.0 - 172.0 ppm) of the 3-iodopropionate 60.  
*IUPAC name: methyl N-(tert-butoxycarbonyl)-L-serinate (62) 
 
    





*IUPAC names: 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (63) 
 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl-1-isothiouronium bromide (64) 
  
    
The attention then turned to preparing the 1-thioglucopyranose 21 and coupling this with the 








Scheme 28: Reagents and conditions: i) 33 % HBr in AcOH, DCM, 0 ºC for 1 h then r.t. for 2 h, 76 %; ii) thiourea, 
acetone, reflux, 2 h, 60 %; iii) Na2S2O5, DCM:H2O (2:1), 50 ºC, 3 h, 95 %; iv) 60, TBAHS, aq. NaHCO3 (0.6 M), EtOAc, 








The first step involved refluxing penta-acetyl glucopyranose 3 with a solution of 33 % HBr in 
acetic acid for 4 h to form the glucosyl bromide 63 which was isolated as a white solid in good 
yield.26 The 1H and 13C NMR spectra, as well as m.p. for the solid were in agreement with 
literature data for this compound, confirming the formation of 63.26 
The glucosyl bromide 63 was then reacted with thiourea in freshly dried acetone at reflux to 
form the isothiouronium bromide salt 64, which had precipitated from solution after 2 h, and 
was obtained as a white solid in moderate yield.26 This was confirmed by the 1H NMR spectrum 
of the solid which showed two-proton singlets at 9.23 and 9.07 ppm, corresponding to the 
amino groups of the thiourea moiety. 
Subsequent treatment of the isothiouronium bromide salt 64 with sodium metabisulphite in a 
mixture of dichloromethane and water at 50 ºC gave the 1-thioglucopyranose 21, isolated as a 
white solid in high yield.26 The 1H NMR spectrum, shown below (Figure 18), of the solid showed 
the presence of a one-proton doublet at 2.30 ppm consistent with the presence of the free thiol 
at the anomeric position, having a β-configuration, confirming the formation of 21. 






                                                            
 
Figure 18: The 1H NMR spectrum (1.90 - 5.30 ppm) of the 1-thioglucopyranose 21.  
   
The final step then required the SN2 substitution of 60 (in a slight excess) with                                
1-thioglucopyranose 21, and this was carried out under basic conditions in a mixture of freshly 
distilled ethyl acetate and water under phase-transfer catalyzed conditions using  
tetrabutylammonium hydrogen sulfate (TBAHS), and at 40 ºC in order to ensure complete 
solubility of the reagents.27 After 4 h TLC showed the complete consumption of 21 and 
formation of a single less polar product which was isolated as a white solid in good yield.          
The 1H NMR spectrum of the solid was consistent with those reported in literature, confirming 
the formation of 61.21 It was noted that the reported procedure made use of an excess of 21 
and a differently protected 3-bromopropionate derivative, but in our procedure an excess of the 
3-iodopropionate 60 made chromatographic purification less troublesome, despite a relative 
reduction in yield of approximately 10 %.27 
With the desired S-glucosylcysteine derivative 61 in hand the attention now shifted to resuming 









*IUPAC name: methyl S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-L-cysteinate trifluoroacetate (65) 
  
2.5.2. Synthesis of the target SGC probe  
 
The final steps of the sequence towards the SGC probe; involved N-deprotection, followed              
by N-acylation with the required tether and then final global deprotection as outlined in                       




Scheme 29: Reagents and conditions; i) TFA, DCM, 0 ºC for 1 h then r.t. for 2 h; ii) 45, NEt3, DCM, 0 ºC for 1 h then 
r.t. for 35 h, 69 % over two steps; iii) NaOMe (0.1 M), MeOH, r.t., 1 h; iv) TFA, DCM, 0 ºC for 1 h then r.t. for 2 h, 63 %               




In the first step the N-Boc group was removed under standard conditions (TFA/DCM) to give the 
amine 65 which was isolated as a colourless oil.72 This was confirmed by the 1H NMR spectrum, 
depicted below (Figure 19), of the oil which showed the disappearance of the nine-proton 
singlet at 1.44 ppm for the carbamate of 61, consistent with the formation of the amine.              
The presence of the TFA counterion was evident from the three-fluorine singlet at -75.5 ppm in 
the 19F NMR spectrum. It must be noted, however, that when this reaction was conducted on a 
large scale (≈ 1.00 g) the removal of residual solvent proved rather time consuming. In light of 
this the amine 65 was taken forward to the next step without further drying.  
The amine 65 was then subjected to the same N-acylation method that led to the formation of 
protected N-acyl cysteine derivatives 42 and 44 in dichloromethane, as described earlier.47          
After 36 h TLC revealed the disappearance of the succinimidyl ester 45 together with the 
formation of a less polar product, which was duly isolated as a colourless oil in good yield. 





*IUPAC names: methyl N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-L-cysteinate (66) 
 methyl N-(6-aminohexanoyl)-S-(β-D-glucopyranosyl)-L-cysteinate trifluoroacetate (67) 
 









Figure 19: The 1H NMR spectrum (2.00 - 5.60 ppm) of the amine product 65, obtained from the N-Boc deprotection 





The 1H NMR spectrum of the oil included a one-proton doublet at 6.41 ppm consistent with             
the presence of the amide bond, confirming the formation of tethered cysteinyl glucoside                       
66. The formation of 66 was further corroborated by the 13C NMR spectrum having 25 signals, 
which correlated to the required 29 carbon atoms taking into account signals which coincide 
due to symmetry and signal overlap, and the detection in the HRMS spectrum of a molecular 
ion [M + H]+ of the required m/z 679.2758. 
Global de-O-acetylation of 66 was then achieved under typical Zemplén conditions                   
(cat. NaOMe in MeOH)75 and subsequent N-Boc deprotection, again under standard conditions 
(TFA/DCM), gave the deprotected cysteinyl glucoside 67 which was isolated as an off-yellow oil 
in moderate yield. This was confirmed by the 1H NMR spectrum of the oil which showed the 
disappearance of the five singlets for the tert-butyl and acetyl protons, of 66, consistent with 
the formation of deprotected glucoside 67. The formation of 67 was further corroborated by 
the 13C NMR spectrum having the required 17 signals, and the detection in the HRMS spectrum 
of a molecular ion [M]+ of the required m/z 411.1800. 





With the successful preparation of the SGC probe in a moderate yield; the attention turned 
establishing whether the methodology could be used to introduce an alternative sugar unit. 
 
2.5.3. Synthesis of the target SAGC probe 
 
The incorporation of an alternative sugar unit to that of glucopyranose was pursued for three 
prominent reasons. Firstly it would afford an opportunity to test the generality of the new 
synthetic approach to glycosyl cysteine probes. Secondly it would allow for the incorporation of 
sugar units more commonly found in biologically relevant glycans. Thirdly it would be the 
starting point for the generation of a library of glycosyl cysteine probes. 
For this investigation mannopyranose, galactopyranose and the 2-acetamido glucopyranose 54 
were all considered as viable sugar units in the first instance, with the incorporation of 54 being 
pursued as a proof-of-concept. The synthesis of the SAGC probe, pleasingly, was also successful 








Scheme 30: Reagents and conditions; i) AcCl, DCM, 30 ºC, 14 h, ≈ 57 %; ii) thiourea, acetone, reflux, 2 h, ≈ 64 %;           




   
As illustrated (Scheme 30) the key S-glycosylcysteine derivative 68 was prepared from the 
isothiouronium chloride salt 70, as described earlier for its 2-O-acetyl analogue 61. Details for 
the synthesis and characterization of compounds 68, 70 and 71 are equivalent to those 
described earlier for their 2-O-acetyl analogues.24,26,27,76,77   
*IUPAC names: methyl N-(tert-butoxycarbonyl)-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-L-cysteinate (68)  
  2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl-1-isothiouronium chloride (70)   
  2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-β-D-glucopyranose (71) 
 





The only discrepancy in the above sequence (Scheme 30) took place during the first step in 
which the glycosyl chloride 69 was isolated with a small amount of the α-glycosyl acetate 55 
during attempts to convert 54 exclusively to 69, through treatment with acetyl chloride for 14 h 
as shown in Scheme 31.76 They were obtained in a ratio of 9:1 (69:55) as judged from 
integration of their respective anomeric proton signals in the 1H NMR spectrum. The products 
were not separated from each other, on the basis that the subsequent step would afford the 
precipitated isothiouronium chloride salt 70, leaving the undesired α-glycosyl acetate 55 in 




Scheme 31: Reagents and conditions: i) AcCl, DCM, 30 ºC, 14 h, (69, ≈ 57 %) and (55, ≈ 6 %). 
 
With the desired S-glycosylcysteine derivative 68 in hand the final steps of the sequence 
towards the SAGC probe were equivalent to those that led to the formation of the SGC probe 




Scheme 32: Reagents and conditions; i) TFA, DCM, 0 ºC for 1 h then r.t. for 2 h; ii) 45, NEt3, DCM, 0 ºC for 1 h then 
r.t. for 35 h, 78 % over two steps; iii) NaOMe (0.1 M), MeOH, r.t., 1 h; iv) TFA, DCM, 0 ºC for 1 h then r.t. for 2 h,          
69 % over two steps. 
*IUPAC name: 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride (69) 





*IUPAC names: methyl S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-L-cysteinate trifluoroacetate (72)  
methyl N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-S-(2-acetamido-tri-3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranosyl)-                                                                              
.L-cysteinate (73)  
   
Briefly, the N-Boc group of 68 was removed under standard N-Boc deprotection conditions 
(TFA/DCM) to form the amine 72 which was isolated as a colourless oil.72 The amine 72 too was 
taken forward without extensive removal of stubborn residual solvent. The formation of 72 was 
confirmed for the same reasons as described earlier for its 2-O-acetyl counterpart 65.  
The amine 72 was then subjected to the same N-acylation method that led to the formation of 
the tethered cysteinyl glucoside 66 in dichloromethane, with the desired amide product 73 
being isolated as a white solid in good yield.47 A comparison of the 1H NMR spectra (Figure 20) 
for isolated compounds 66 and 73 are compared to highlight the shielding of H-2’ from                    
5.00 ppm to 4.00 ppm in going from compound 66 to 73. Shifts of this magnitude were found to 
be common when comparing the 1H NMR spectra of the 2-O-acetyl derivatives to their                         
2-acetamido analogues. The formation of 73 was further corroborated by the detection in the 




Figure 20: A comparison of the 1H NMR spectra (1.90 - 6.70 ppm) of tethered cysteinyl glycosides 66 and 73, with                     
key signals assigned. 





Global de-O-acetylation of 73 and subsequent N-Boc deprotection was achieved, again under 
the same conditions72,75 that led to the formation of 67, and gave the deprotected cysteinyl 
glycoside 74, being isolated as a cream coloured oil in moderate yield. For confirmatory 
purposes a section of the HSQC spectrum (Figure 21) of the isolated target SAGC 74 is given, 
with all heteronuclear couplings assigned. The formation of 74 was further corroborated by the 

















Figure 21: The HSQC spectrum (δH: 1.50 - 5.00 ppm/ δC: 20.0 - 90.0 ppm), of target SAGC 74, referenced with 





*IUPAC name: methyl N-(6-aminohexanoyl)-S-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-L-cysteinate trifluoroacetate (74) 
  

























3.  Conclusion and Future Work 
3.1. Conclusion 
 
During the course of this project directed at the synthesis of cysteine-based glycan-binding 
probes it was found that: 
The novel SGC probe 67 can be readily prepared in good yields from the S-glucosylcysteine 
derivative 61, in a short, four-step sequence involving; N-Boc deprotection, N-acylation with the 
succinimidyl ester 45, and finally a combination of de-O-acetylation and N-Boc deprotection.     
An alternative and more direct method, via treatment of penta-acetyl glucopyranose 3 with the 
N-Boc-GA 40 under Lewis acid promotion followed by N-Boc deprotection is still a worthwhile 
option, but requires further careful evaluation and optimization of reaction conditions.                
The S-glucosylcysteine derivative 61 in turn was prepared in good yields from 3, in a short,              
four-step sequence starting with formation of a glucosyl halide, conversion of this to an 
isothiouronium salt, mild hydrolysis to generate the glucosyl thiol, and finally reaction of this 
thiol with the 3-iodopropanoate 60. The above 8-step sequence was successfully replicated to 
afford the SAGC probe 74, starting with 2-acetamido-2-deoxy-D-glucopyranose 54. 
Attempts at identifying efficient reaction conditions for a one-pot, bis-glucosylation of N-acetyl-
L-cysteine 4 with 3 met with limited success: as in almost all cases instances of anomerization, 
hydrolysis, chloridation and mono-glucosylation of 3 were observed. An attempt at similar                 
bis-glucosylation of N-acyl cysteine 12 with 3 was also unsuccessful. In addition, attempts at the                    
mono-glycosylation of methyl N-acetyl-L-cysteinate 20 with the 2-deoxy-glycosyl acetates 52, 53 
and 57, under SnCl4 promotion, did not lead to the formation of the desired S-glycosylcysteine 
products, suggesting that they are not sufficiently reactive under the conditions used. This was 
an unexpected result, but does highlight that glycosyl acetates are not regarded as the best 
glycosyl donors. The selective removal of S-protecting groups via base-catalyzed elimination 
followed by disulfide bond cleavage (tert-butyl of 42) or hydrogenation (benzyl of 44), did not 
take place under the conditions used. 





3.2. Future work 
  
Despite initial target bis-glucoside 11 not being obtained its unusual pattern of bis-glucosylation 
still holds great promise for the incorporation into a variety of molecular tools. The major 
challenge faced during its synthesis was the bis-glucosylation of N-acyl cysteine 12 with 3.                 
This suggests a new step-wise synthetic route, which makes use of the methodology described 
earlier, as outlined in Scheme 33.78 The key step in this alternative route is the stereoselective 
glucosylation of the carboxylic acid group in 76 to afford the α-acylglucoside 77. This will need 
to be carefully investigated, as the formation of an α-acylglucoside in the presence 
neighbouring group participation is one of the most challenging reactions in glycochemistry. 
Nonetheless, if difficulties are encountered during this step and the β-acylglucoside is obtained 







Scheme 33: Reagents and conditions; i) TFA, DCM, 0 ºC for 1 h then r.t. for 2 h; ii) 45, NEt3, DCM, 0 ºC for 1 h then 
r.t. for 35 h; iii) 28 (α-anomer), DMAP (cat.), EDC.HCl, DCM, r.t.; iv) NaOMe (0.1 M), MeOH, r.t., 1 h; v) TFA, DCM,                











If successful this would be the starting point for the generation of a library of potential                                     
bis-glycosyl cysteine probes, as was demonstrated earlier for the mono-glycosyl cysteine 
derivatives. Once this has been achieved, it would then be possible to extend this work to the 
development of novel glycoarrays in which a targeted CBP could be probed for. 





In addition to the above, this methodology could be easily adapted to produce                                       
S-glycosylceramides such as 79, shown in Scheme 34.79,80 These O-glycosylceramide analogues 
are of particular interest, as they aid in the generation and biological evaluation of                             
new glycolipid antigens, and have been found to be more stable during in vivo studies.79                      
More specifically, ceramide 79 is an analogue of α-GalCer 8 and could be used to study the           
















Scheme 34: An envisioned approach towards the S-galactosylceramide 79, an analogue of α-GalCer 8. Its synthesis 
would involve use of the methodology established in the synthesis of SGC 67 and SAGC 74. The incorporation of the 
tetradecyl ester (red) and the anomerization of the β-thiogalactoside linkage to an α-thiogalactoside linkage (blue) 
are the only two key adaptations to the established methodology to be implemented. 






























All commercial reagents were purchased from Sigma-Aldrich and used as received. All solvents 
were purchased either from Sigma-Aldrich or Kimix Chemical And Lab Supply Cc. Dry or freshly 
distilled solvents were used when reactions were carried out under an anhydrous, inert, 
atmosphere under a continuous flow of argon gas. Dichloromethane was dried over calcium 
hydride, and distilled under argon gas.  
All reactions were monitored by TLC carried out on pre-coated Merck 60 F254 silica gel alumina 
plates using an ascending technique. The plates were visualized with UV-light (254 nm) or by 
spraying with solutions of either ceric ammonium sulfate (5.00 g CAS, 50 ml ethanol, 50 mL        
2.0 M H2SO4), ninhydrin (200 mg ninhydrin, 97 mL ethanol, 3 mL glacial acetic acid)                         
or bromocresol green (100 mg bromocresol green, 500 ml ethanol, 5 ml 0.1 M NaOH).                    
Gravity column chromatography was performed using Merck silica gel 60 (70-230 mesh).                       
All compounds were dried in vacuo before yields were determined. 
Melting points were determined using a Reichert-Jung Thermovar hot-stage microscope and           
are uncorrected. NMR spectra (1H, 13C and 19F NMR) were recorded on either a Bruker 
(400/101/377 MHz) or Varian Unity (300 MHz) instrument at 30 °C and are referenced with 
respect to the deuterated solvent peak, unless stated otherwise. All chemical shifts (δ) are 
recorded in ppm with respect to TMS and coupling constants (J-values) reported in Hertz (Hz); 
with signals assigned according to the numbering designated, (H-1 = H on C-1). The numbering 
scheme given for each compound is for assignment purposes only and not necessarily 
consistent with the IUPAC naming convention. IR spectra were recorded on a Perkin-Elmer 
UATR Two spectrophotometer. HRMS spectra were recorded on a Waters Synapt G2 machine                 
in ESI+ mode, which was performed at the Central Analytical Facilities (CAF), School of 
Chemistry, Stellenbosch University.  





4.2. Experimental methods 
  




To an aqueous solution of HBr (48 % in H2O, 29 mL) and conc. H2SO4 (7 mL) at 0 ºC, was              
added γ-butyrolactone 15 (4.00 mL, 52.0 mmol) and the stirred reaction mixture allowed to 
warm to room temperature over 1 h. The reaction mixture was then heated at reflux for                         
14 h, cooled to room temperature and diluted with water (135 mL). The resulting solution was 
extracted with diethyl ether (4 x 40 mL), and the combined organic extracts washed with                                    
sat. brine (40 mL), dried over Na2SO4 and filtered. The filtrate was concentrated under reduced 
pressure and the resulting residue dried in vacuo (at 1.0 mbar) to afford 16 as a yellow solid                                      
(6.25 g, 37.4 mmol, 72 %).                                
 
M.p. 29-30 ºC, (lit.31 32 ºC). 1H NMR: H (CDCl3, 300 MHz) 3.48 (2H, t, J = 6.4 Hz, H-4), 2.57          
(2H, t, J = 7.1 Hz, H-2), 2.18 (2H, p, J = 6.7 Hz, H-3). 13C NMR: C (CDCl3, 101 MHz) 179.0 (C-1), 
32.4 (C-2, C-4), 27.6 (C-3).13  
 
methyl 4-bromobutanoate (26)32,81 
 
To a solution of 16 (2.00 g, 12.0 mmol) in methanol (12 mL) at room temperature, was added 
conc. H2SO4 (4 drops) and the reaction mixture heated at reflux for 3 h. The reaction mixture 
was then cooled to room temperature, diluted with dichloromethane (20 mL) and washed 
sequentially with sat. NaHCO3 (20 mL), water (20 mL) and sat. brine (20 mL). The extracted 
organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford 
26 as a colourless, viscous liquid (1.82 g, 10.1 mmol, 84 %).  





1H NMR: H (CDCl3, 300 MHz) 3.67 (3H, s, OCH3) 3.45 (2H, t, J = 6.5 Hz, H-4), 2.49 (2H, t,                    
J = 7.2 Hz, H-2), 2.16 (2H, p, J = 6.9 Hz, H-3). 13C NMR: C (CDCl3, 101 MHz) 173.0 (C-1), 51.8 
(OCH3), 32.7, 32.4, 27.9 (C-3).81 
 
methyl 4-azidobutanoate (27)33,35,36  
 
To a solution of 26 (1.74 g, 9.61 mmol) in dimethyl sulfoxide (12 mL) at room temperature, was 
added sodium azide (0.938 g, 14.4 mmol) and the reaction mixture heated at 50 ºC for 4 h.         
The reaction mixture was then cooled to room temperature, diluted with diethyl ether (50 mL) 
and the resulting precipitate recovered by filtration. The filtrate was washed sequentially with 
sat. NaHCO3 (3 x 20 mL), water (3 x 20 mL) and sat. brine (3 x 20 mL). The extracted organic layer 
was dried over MgSO4 for 24 h, filtered and concentrated under reduced pressure to afford 27 
as a off-yellow, viscous liquid (0.662 g, 4.62 mmol, 48 %).  
 
IR: νmax (ATR, cm-1) 2095 (N=N=N), 1733 (C=O). 1H NMR: H (CDCl3, 300 MHz) 3.67 (3H, s, OCH3) 
3.33 (2H, t, J = 6.7 Hz, H-4), 2.40 (2H, t, J = 7.2 Hz, H-2), 1.89 (2H, p, J = 6.9 Hz, H-3).                    












4-azidobutanoic acid (17)34-36  
 
A suspension of 27 (0.604 g, 4.22 mmol) in aq. NaOH (1.0 M, 5 mL) at room temperature, was 
treated with a small amount of methanol (0.15 mL) and stirred vigorously to obtain a 
homogeneous solution after 1 h. After a further 3 h the solution was diluted with diethyl ether 
(20 mL) and the extracted aqueous layer acidified (to pH = 1) by dropwise addition of conc. HCl 
before extracting further with diethyl ether (4 x 20 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure to afford 17 as an             
off-yellow, viscous liquid (0.355 g, 2.75 mmol, 65 %).  
 
1H NMR: H (CDCl3, 300 MHz) 9.86 (1H, bs, OH), 3.37 (2H, t, J = 6.7 Hz, H-4), 2.47 (2H, t,                 
J = 7.2 Hz, H-2), 1.91 (2H, p, J = 6.9 Hz, H-3). 13C NMR: C (CDCl3, 101 MHz) 179.1 (C-1), 50.6        
(C-4), 31.0 (C-2), 24.1 (C-3).34-36   
 
General procedure used for the conversion of carboxylic acids to succinimidyl esters 
Procedure (A): To a suspension consisting of the carboxylic acid substrate (1.0 eq.) and             
NHS (1.1 eq.) in dichloromethane (20 mL) at 0 ºC, was added EDC.HCl (1.2 eq.) and the stirred 
reaction mixture allowed to warm to room temperature overnight. The reaction mixture          
was then diluted with dichloromethane (20 mL) and washed sequentially with aq. HCl              
(0.2 M, 3 × 20 mL) and sat. brine (30 mL). The extracted organic layer was dried over        










2,5-dioxopyrrolidin-1-yl 4-azidobutanoate (18)36 
 
Esterification of 17 (0.270 g, 2.09 mmol) was achieved using Procedure A and afforded 18 as a 
colourless oil (0.391 g, 1.72 mmol, 82 %).  
 
1H NMR: H (CDCl3, 300 MHz) 3.44 (2H, t, J = 6.6 Hz, H-4), 2.82 (4H, s, H-2’, H-3’), 2.72 (2H, t,          
J = 7.2 Hz, H-2), 2.01 (2H, p, J = 7.0 Hz, H-3). 13C NMR: C (CDCl3, 101 MHz) 169.1 (C-1’, C-4’), 




To a suspension of L-cysteine hydrochloride 14 (0.132 g, 0.838 mmol) and triethylamine             
(0.12 mL) in dry dimethylformamide (3 mL) at 0 ºC, was added 18 (0.183 g, 0.806 mmol) and the 
stirred reaction mixture allowed to warm to room temperature over 1 h. After a further 13 h the 
reaction mixture was then quenched with cold water (40 mL) and diluted with ethyl acetate       
(30 mL). The separated aqueous layer was acidified (to pH = 2) by dropwise addition of                    
conc. HCl, before extracting further with cold ethyl acetate (3 x 20 mL) and washing the 
combined organic layers repeatedly with aq. LiCl (10 % w/v, 5 x 10 mL). The combined organic 
extracts were dried over Na2SO4, filtered and solvents removed by azeotropic distillation after 
addition of toluene, to afford 12 as a crude, off-yellow oil (0.084 g, 0.362 mmol, 45 %).  
 





1H NMR: H (CDCl3, 300 MHz) 6.67 (1H, d, J = 7.5 Hz, NHCOR), 4.89 (1H, dt, J = 7.5, 4.3 Hz, H-2), 
3.39 (2H, t, J = 6.5 Hz, H-4’), 3.18-2.94 (2H, m, H-3), 2.42 (2H, t, J = 7.2 Hz, H-2’), 1.95 (2H, p,         
J = 6.8 Hz, H-3’), 1.49 (1H, t, J = 9.0 Hz, SH). Further analysis was not conducted on the basis of 







To a mixture of penta-acetyl glucopyranose 3 (0.504 g, 1.29 mmol) and N-acetyl-L-cysteine 4 
(0.098 g, 0.601 mmol) in dry dichloromethane (5 mL) at room temperature, was added SnCl4            
(1.0 M in DCM, 1.50 mL, 1.50 mmol) dropwise and the reaction mixture left to stir for 3 h.                   
The reaction mixture was then diluted with dichloromethane (15 mL) and washed sequentially 
with aq. HCl (1.0 M, 2 × 10 mL). The extracted organic layer was dried over Na2SO4,                      
filtered and concentrated under reduced pressure to give the crude product. This was                   
then purified via gradient column chromatography (1-5 % methanol in dichloromethane) and 
the pooled fractions concentrated under reduced pressure to afford 1 as a colourless oil                   
(0.058 g, 0.072 mmol, 12 %).  
 
1H NMR: H (CDCl3, 300 MHz) 6.53 (1H, d, J = 7.3 Hz, NHCOCH3), 6.33 (1H, d, J = 3.6 Hz, H-1’’), 
5.46 (1H, t, J = 9.8 Hz), 5.24 (1H, t, J = 9.6 Hz), 5.04-5.17 (3H, m), 5.00 (1H, t, J = 9.5 Hz),                
4.90-4.84 (1H, m, H-2), 4.56 (1H, d, J = 10.1 Hz, H-1’), 4.25-4.05 (5H, m), 3.75 (1H, m), 3.23 (1H, 
dd, J = 14.4, 4.7 Hz, H-3), 3.16 (1H, dd, J = 14.4, 6.2 Hz, H-3), 2.04-1.95 (27H, m, 8 × COCH3, 
NHCOCH3). Further analysis was not conducted on the basis of the compound being impure; 
however the above experimental data is in good agreement with the reported literature data.7 
 










To a suspension of sodium azide (4.00 g, 61.5 mmol) in acetonitrile (60 mL) at 0 ºC, was added 
sulfuryl chloride 37 (4.95 mL, 61.3 mmol) and the stirred reaction mixture allowed to warm to 
room temperature overnight. The reaction mixture was then cooled to 0 ºC again before adding 
imidazole (7.96 g, 117 mmol) and then allowing the reaction mixture to warm to room 
temperature over 30 min. After a further 3 h the reaction mixture was diluted with ethyl acetate 
(60 mL) and washed sequentially with water (2 × 150 mL) and sat. NaHCO3 (2 × 150 mL).         
The extracted organic layer was dried over Na2SO4, filtered and cooled to 0 ºC.  A solution of HCl 
in ethanol [generated in situ from the dropwise addition of excess acetyl chloride                             
(6 mL) to ethanol (24 mL) at 0 ºC] was then added dropwise to the filtrate together with 
vigorous stirring. The resulting precipitate was recovered by filtration and washed with small 





M.p. 100-101 ºC, (lit.42 100-102 ºC). IR: νmax (ATR, cm-1) 2169 (N=N=N), 1425 (S=O), 1160 (S=O).    
1H NMR: H (D2O, 300 MHz) 9.38 (1H, dd, J = 1.6, 1.2 Hz, H-1), 8.08 (1H, dd, J = 2.1, 1.6 Hz, H-3), 













6-azidohexanoic acid (34)43 
 
 
To a suspension of 6-aminohexanoic acid 32 (2.00 g, 15.2 mmol), K2CO3 (4.64 g, 33.6 mmol)      
and CuSO4.5H2O (2.7 mol %) in methanol (40 mL) at room temperature, was added the sulfonyl 
azide 33 (3.84 g, 18.3 mmol) and the reaction mixture left to stir for 16 h. The reaction mixture 
was then concentrated under reduced pressure and the resulting residue re-dissolved in        
water (30 mL). The aqueous solution was washed repeatedly with dichloromethane (6 x 30 mL) 
and the extracted aqueous layer acidified (to pH = 2) by dropwise addition of aq. HCl (1.0 M) 
before extracting further with diethyl ether (6 x 30 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product.               
This was then purified via gradient column chromatography (20-80 % ethyl acetate in hexane) 
and the pooled fractions concentrated under reduced pressure to afford 34 as an off-yellow oil 






IR: νmax (ATR, cm-1) 3120 (O-H), 2090 (N=N=N), 1704 (C=O). 1H NMR: H (CDCl3, 300 MHz) 9.11 
(1H, bs, OH), 3.28 (2H, t, J = 6.8 Hz, H-6), 2.38 (2H, t, J = 7.4 Hz, H-2), 1.73-1.58 (4H, m, H-3, H-5), 
1.49-1.38 (2H, m, H-4). 13C NMR: C (CDCl3, 101 MHz) 179.9 (C-1), 51.3 (C-6), 34.0 (C-2), 28.7             














2,5-dioxopyrrolidin-1-yl 6-azidohexanoate (35)14 
 
Esterification of 34 (0.546 g, 3.47 mmol) was achieved using Procedure A and afforded 35 as an 
off-yellow oil (0.661 g, 2.60 mmol, 75 %). 
  
1H NMR: H (CDCl3, 300 MHz) 3.29 (2H, t, J = 6.7 Hz, H-6), 2.82 (4H, s, H-2’, H-3’) 2.62 (2H, t,          
J = 7.3 Hz, H-2), 1.78 (2H, p, J = 7.4 Hz, H-3), 1.68-1.59 (2H, m, H-5), 1.55-1.45 (2H, m, H-4).        
13C NMR: C (CDCl3, 101 MHz) 169.2 (C-1’, C-4’), 168.5 (C-1), 51.3 (C-6), 30.9 (C-2), 28.5 (C-5), 
26.0 (C-4), 25.7 (C-2’, C-3’), 24.3 (C-3).14 
 
6-((tert-butyloxycarbonyl)amino)hexanoic acid (46)55,56,82  
 
 
To a mixture of 6-aminohexanoic acid 32 (2.00 g, 15.2 mmol) and Boc-anhydride                     
(3.32 g, 15.2 mmol) in methanol (40 mL) at room temperature, was added triethylamine                    
(2.60 mL, 18.7 mmol) and the reaction mixture heated at reflux for 24 h. The reaction mixture 
was then cooled to room temperature, concentrated under reduced pressure and the resulting 
residue re-dissolved in ethyl acetate (40 mL). The organic solution was washed with aq. HCl                
(0.2 M, 2 × 50 mL), dried over Na2SO4 and filtered. The filtrate was then concentrated under 
reduced pressure to give a colourless oil which solidified upon storage at -18 ºC. The resulting 
crude solid was dried in vacuo and then purified via recrystallization from hexane to afford 46 as 
a white solid (3.09 g, 13.4 mmol, 88 %).   
 





M.p. 37-39 ºC, (lit.82 38-39 ºC). 1H NMR: H (CDCl3, 300 MHz) 4.57 (1H, bs, NHCOOR), 3.10          
(2H, q, J = 6.3 Hz, H-6), 2.34 (2H, t, J = 7.4 Hz, H-2), 1.64 (2H, p, J = 7.4 Hz, H-3), 1.53-1.32         
(4H, m, H-4, H-5), 1.43 (9H, s, 3 × C(CH3)). 13C NMR: C (CDCl3, 101 MHz) 179.0 (C-1), 156.2 
(NHCOOR), 79.3 (C(CH3)3), 40.5 (C-6), 34.0 (C-2), 29.8 (C-5), 28.6 (3 × C(CH3)), 26.4 (C-4),           
24.5 (C-3).56,82  
 
2,5-dioxopyrrolidin-1-yl 6-((tert-butoxycarbonyl)amino)hexanoate (45)56,83 
 
Esterification of 46 (3.00 g, 13.0 mmol) was achieved using Procedure A and afforded 45 as a 
white solid (3.68 g, 11.2 mmol, 86 %).  
 
M.p. 88-91 ºC, (lit.83 87-89 ºC). 1H NMR: H (CDCl3, 300 MHz) 4.59 (1H, bs, NHCOOR), 3.11 (2H, q,   
J = 6.3 Hz, H-6), 2.81 (4H, s, H-2’, H-3’), 2.59 (2H, t, J = 7.3 Hz, H-2), 1.76 (2H, p, J = 7.4 Hz, H-3), 
1.56-1.37 (4H, m, H-4, H-5), 1.43 (9H, s, 3 × C(CH3)). 13C NMR: C (CDCl3, 101 MHz) 169.2               
(C-1’, C-4’), 168.6 (C-1), 156.1 (NHCOOR), 79.2 (C(CH3)3), 40.4 (C-6), 31.0 (C-2), 29.7 (C-5), 28.5                  
(3 × C(CH3)), 26.0 (C-4), 25.7 (C-2’, C-3’), 24.4 (C-3).56,83 Note that compound 45 was prepared 












methyl S-(tert-butyl)-L-cysteinate trifluoroacetate (41)84 
 
 
To a solution of methyl L-cysteinate hydrochloride 36 (1.50 g, 8.74 mmol) in TFA (10 mL) at room 
temperature, was added tert-butanol (0.85 mL, 8.89 mmol) and the reaction mixture left to stir 
for 18 h. Excess TFA was then evaporated off under a steady-stream of air and the resulting 
solid-like residue suspended in a minimal amount of cold water. The residue was quickly 
recovered by filtration and washed with small amounts of cold water to afford 41 as a white 
wax-like solid (1.68 g, 5.50 mmol, 63 %). 
 
1H NMR: H (CDCl3, 300 MHz) 7.61 (2H, bs, NH2), 4.22 (1H, dd, J = 6.5, 5.4 Hz, H-2), 3.82             
(3H, s, OCH3), 3.18 (1H, dd, J = 13.7, 5.4 Hz, H-3), 3.11 (1H, dd, J = 13.7, 6.5 Hz, H-3), 1.33          
(9H, s, 3 × C(CH3)). 13C NMR: C (CDCl3, 101 MHz) 168.5 (C-1), 53.6, 53.1, 44.0 (C(CH3)3), 30.8                    
(3 × C(CH3)), 28.6 (C-3). 19F NMR: C (CDCl3, 377 MHz) -75.7 (3F, s, COCF3). 
 
General procedure used for the conversion of amines to amides  
  
Procedure (B): To a solution of the S-protected/glycosyl cysteine substrate (1.1-1.3 eq.) in 
dichloromethane (10 mL) at 0 ºC, was added triethylamine (1.4 eq.) and the reaction mixture 
left to stir for 30 min, at which point the succinimidyl ester 45 (1.0 eq.) was added. The stirred 
reaction mixture was then allowed to warm to room temperature over 30 min and after a 
further 23-35 h the reaction mixture was diluted with dichloromethane (20 mL) and washed 
sequentially with aq. HCl (0.2 M, 5 × 20 mL) and sat. brine (30 mL). The extracted organic                
layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the                   
crude product. This was then purified via column chromatography and the pooled fractions 
concentrated under reduced pressure to afford the desired amide product.47  
 





methyl N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-S-(tert-butyl)-L-cysteinate (42) 
 
 
Amide coupling of 41 (0.610 g, 2.00 mmol) with the succinimidyl ester 45 (0.496 g, 1.51 mmol) 
was achieved using Procedure B and afforded 42 as a colourless oil (0.393 g, 0.971 mmol, 64 %) 
after purification via gradient column chromatography (50-100 % ethyl acetate in hexane). 
 
1H NMR: H (CDCl3, 400 MHz) 6.23 (1H, d, J = 7.5 Hz, NHCOR), 4.85 (1H, dt, J = 7.5, 4.9 Hz, H-2), 
4.57 (1H, bs, NHCOOR), 3.75 (3H, s, OCH3), 3.09 (2H, q, J = 6.4 Hz, H-6’), 3.03-2.95 (2H, m, H-3), 
2.23 (2H, t, J = 7.5 Hz, H-2’), 1.65 (2H, p, J = 7.4 Hz, H-3’), 1.52-1.32 (4H, m, H-4’, H-5’), 1.43      
(9H, s, 3 × OC(CH3)), 1.29 (9H, s, 3 × SC(CH3)). 13C NMR: C (CDCl3, 101 MHz) 172.7, 171.4, 156.1 
(NHCOOR), 79.2 (OC(CH3)3), 52.7 (OCH3), 51.9 (C-2), 42.8 (SC(CH3)3), 40.5 (C-6’), 36.4 (C-2’), 31.0 
(3 × SC(CH3)), 30.6 (C-3), 29.9 (C-5’), 28.6 (3 × OC(CH3)), 26.4 (C-4’), 25.2 (C-3’). HRMS (ESI+): m/z 
calculated for C19H36N2O5S, 404.2345; found 405.2419 [M + H]+.   
 
S-benzyl-L-cysteine hydrochloride (48)51 
 
To a rapidly stirring solution of aq. NaOH (2.0 M, 11 mL) and ethanol (25 mL) at room 
temperature, was added L-cysteine hydrochloride 14 (0.904 g, 5.74 mmol) followed by dropwise 
addition of benzyl bromide (0.70 mL, 5.89 mmol). After 1 h, the reaction mixture was acidified 
(to pH = 2) by addition of conc. HCl and the resulting precipitate recovered by filtration.                 
The precipitate was then washed sequentially with small amounts of cold water, ethanol and 
dichloromethane to afford 48 as a white crystalline solid (1.01 g, 4.08 mmol, 71 %). 





M.p. 201-204 ºC, (lit.51 210-211 ºC). 1H NMR: H (D2O, 300 MHz) 7.29-7.09 (5H, m, 5 × Ar-H), 3.95 
(1H, dd, J = 7.6, 4.6 Hz, H-2), 3.64 (2H, s, SCH2Ar), 2.87 (1H, dd, J = 15.0, 4.6 Hz, H-3), 2.76        
(1H, dd, J = 15.0, 7.6 Hz, H-3). 13C NMR: C (D2O, 101 MHz) 170.2 (C-1), 137.5 (Ar-C), 129.0          
(2 × Ar-C), 128.9 (2 × Ar-C), 127.6 (Ar-C), 52.0 (C-2), 35.4 (SCH2Ar), 30.5 (C-3).51 
 
methyl S-benzyl-L-cysteinate hydrochloride (43)51  
 
To a solution of HCl in methanol [generated in situ from the dropwise addition of excess acetyl 
chloride (1 mL) to methanol (3 mL) at 0 ºC], was added 48 (0.769 g, 3.10 mmol) and the stirred 
reaction mixture allowed to warm to room temperature over 1 h. After a further 14 h the 
reaction mixture was poured into an evaporating dish and excess volatiles allowed to evaporate 
overnight. The resulting solid was recovered by filtration and washed with small amounts of 
cold diethyl ether to afford 43 as white crystalline solid (0.544 g, 2.08 mmol, 67 %). 
  
M.p. 142-144 ºC, (lit.51 148-150 ºC). 1H NMR: H (CDCl3, 300 MHz) 8.90 (2H, bs, NH2), 7.37-7.18 
(5H, m, 5 × Ar-H), 4.49-4.40 (1H, m, H-2), 3.83 (2H, s, SCH2Ar), 3.74 (3H, s, OCH3), 3.18 (2H, d,       
J = 5.6 Hz, H-3). 13C NMR: C (CDCl3, 101 MHz) 168.7 (C-1), 137.5 (Ar-C), 129.3 (2 × Ar-C), 128.8 











methyl S-benzyl-N-(6-((tert-butoxycarbonyl)amino)hexanoyl)-L-cysteinate (44) 
 
   
Amide coupling of 43 (0.273 g, 1.04 mmol) with the succinimidyl ester 45 (0.251 g, 0.764 mmol) 
was achieved using Procedure B and afforded 44 as a white solid (0.240 g, 0.547 mmol, 72 %) 
after purification via gradient column chromatography (50-100 % ethyl acetate in hexane). 
 
M.p. 83-84 ºC. 1H NMR: H (CDCl3, 400 MHz) 7.34-7.22 (5H, m, 5 × Ar-H), 6.12 (1H, d, J = 7.8 Hz, 
NHCOR), 4.80 (1H, dt, J = 7.8, 5.4 Hz, H-2), 4.54 (1H, bs, NHCOOR), 3.73 (3H, s, OCH3), 3.70      
(2H, s, SCH2Ar), 3.10 (2H, q, J = 6.5 Hz, H-6’), 2.92 (1H, dd, J = 13.8, 5.0 Hz, H-3), 2.85 (1H, dd,       
J = 13.8, 5.7 Hz, H-3), 2.19 (2H, t, J = 7.5 Hz, H-2’), 1.65 (2H, p, J = 7.4 Hz, H-3’), 1.48 (2H, p,           
J = 7.4 Hz, H-5’), 1.43 (9H, s, 3 × C(CH3)), 1.40-1.31 (2H, m, H-4’). 13C NMR: C (CDCl3, 101 MHz) 
172.6, 171.4, 156.0 (NHCOOR), 137.7 (Ar-C), 128.9 (2 × Ar-C), 128.6 (2 × Ar-C),  127.3 (Ar-C), 
79.1 (C(CH3)3), 52.5 (OCH3), 51.5 (C-2), 40.4 (C-6’), 36.7 (SCH2Ar), 36.2 (C-2’), 33.6 (C-3), 29.7      
(C-5’), 28.4 (3 × C(CH3)), 26.3 (C-4’), 25.0 (C-3’). HRMS (ESI+): m/z calculated for C22H34N2O5S, 

























To a solution of methyl L-cysteine hydrochloride 36 (2.87 g, 16.7 mmol) in a H2O:MeCN                 
(1:1, 50 mL) mixture at 0 ºC, was added triethylamine until a basic solution (pH = 9) was 
obtained and the reaction mixture left to stir for 30 min, at which point the succinimidyl ester 
45 (5.00 g, 15.2 mmol) was added. The stirred reaction mixture was then allowed to warm to 
room temperature over 30 min and after a further 17 h the reaction mixture was diluted with 
ethyl acetate (50 mL) and washed sequentially with aq. HCl (0.2 M, 5 × 40 mL) and sat. brine    
(40 mL). The extracted organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure to afford the crude product. This was then purified twice via flash column 
chromatography (100 % ethyl acetate) and the pooled fractions concentrated under pressure to 
afford 40 as a white a solid (4.03 g, 11.6 mmol, 76 %).  
 
M.p. 53-56 ºC. 1H NMR: H (CDCl3, 300 MHz) 6.33 (1H, d, J = 7.4 Hz, NHCOR), 4.88 (1H, dt, J = 7.4, 
4.2 Hz, H-2), 4.54 (1H, bs, NHCOOR), 3.79 (3H, s, OCH3), 3.11 (2H, q, J = 6.4 Hz, H-6’), 3.01                    
(2H, ddd, J = 8.9, 4.3, 4.0 Hz, H-3), 2.27 (2H, t, J = 7.5 Hz, H-2’), 1.67 (2H, p, J = 7.4 Hz, H-3’), 
1.55-1.32 (4H, m, H-4’, H-5’), 1.43 (9H, s, 3 × C(CH3)), 1.33 (1H, t, J = 8.9 Hz, SH). 13C NMR: C 
(CDCl3, 101 MHz) 172.8, 170.8, 156.1 (NHCOOR), 79.1 (C(CH3)3), 53.5 (C-2), 52.8 (OCH3), 40.4    
(C-6’), 36.3 (C-2’), 29.8 (C-5’), 28.5 (3 × C(CH3)), 26.9 (C-3), 26.4 (C-4’), 25.2 (C-3’). HRMS (ESI+): 











methyl S-(6-((tert-butoxycarbonyl)amino)hexanoyl)-L-cysteinate (49) 
 
Compound 49 was isolated as a white solid (0.883 g, 2.53 mmol, 17 %) being the minor product 




M.p. 110-114 ºC. 1H NMR: H (CDCl3, 300 MHz) 6.58 (2H, bs, NH2), 4.82 (1H, dt, J = 7.4, 5.4 Hz,    
H-2), 4.67 (1H, bs, NHCOOR), 3.75 (3H, s, OCH3), 3.16 (2H, d, J = 5.4 Hz, H-3), 3.11 (2H, q, J = 6.5 
Hz, H-6’), 2.24 (2H, t, J = 7.4 Hz, H-2’), 1.64 (2H, p, J = 7.4 Hz, H-3’), 1.52-1.30 (4H, m, H-4’, H-5’), 
1.41 (9H, s, 3 × C(CH3)). 13C NMR: C (CDCl3, 101 MHz) 173.0, 171.1, 156.2 (NHCOOR), 79.1 
(C(CH3)3), 52.8 (OCH3), 51.8 (C-2), 40.8 (C-3), 40.5 (C-6’) 36.2 (C-2’), 29.8 (C-5’), 28.5 (3 × C(CH3)), 
26.4 (C-4’), 25.1 (C-3’). HRMS (ESI+): m/z calculated for C15H28N2O5S, 348.1719; found                   
349.1783 [M + H]+. 
 
General procedure used for the formation of thioglucosides from glycosyl acetates under 





Procedure (C): To a mixture of penta-acetyl glucopyranose 3 (1.0 eq.) and the cysteine substrate       
(1.5 eq.) in dry dichloromethane (10 mL) at room temperature, was added SnCl4 (2.0 eq.) 
dropwise and the reaction mixture left to stir for 3 h. The reaction mixture was then diluted 
with dichloromethane (20 mL) and washed sequentially with aq. HCl (1.0 M, 2 × 20 mL) and       
sat. brine (30 mL). The extracted organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure to give the crude product. This was then purified via column 
chromatography and the pooled fractions concentrated under reduced pressure to afford the 
desired S-glycosylcysteine product.20 
 
 







Glycosylation of N-acetyl-L-cysteine 4 (0.312 g, 1.91 mmol) with penta-acetyl glucopyranose                  
3 (0.506 g, 1.30 mmol) was achieved using Procedure C and afforded 2 as a white foam                               
(0.215 g, 0.436 mmol, 34 %) after purification via gradient column chromatography (1-10 % 
methanol in dichloromethane). 
   
 
1H NMR: H (CD3OD, 400 MHz) 5.28 (1H, t, J = 9.3 Hz, H-3’), 5.04 (1H, t, J = 9.8 Hz, H-4’), 4.93     
(1H, t, J = 9.7 Hz, H-2’), 4.78 (1H, d, J = 10.1 Hz, H-1’), 4.50 (1H, dd, J = 8.2, 4.5 Hz, H-2), 4.27     
(1H, dd, J = 12.5, 4.7 Hz, H-6’), 4.18 (1H, dd, J = 12.5, 2.3 Hz, H-6’), 3.89 (1H, ddd, J = 10.1, 4.7,        
2.3 Hz, H-5’), 3.26 (1H, dd, J = 13.8, 4.5 Hz, H-3), 2.94 (1H, dd, J = 13.8, 8.2 Hz, H-3), [2.07, 2.03, 
2.01, 1.97 (15H, 4s, 4 × COCH3, NHCOCH3)]. 13C NMR: C (CD3OD, 101 MHz) [176.3, 173.1, 172.4, 
171.6, 171.3, 171.2 (4 × COCH3, NHCOCH3, C-1)], 84.1 (C-1’), 76.9 (C-5’), 75.2 (C-3’), 71.6                            
(C-2’), 69.8 (C-4’), 63.3 (C-6’), 55.1 (C-2), 33.0 (C-3), 22.7 (NHCOCH3), 20.7 (2 × COCH3), 20.5                   




















Glycosylation of methyl N-acetyl-L-cysteinate 20 (0.338 g, 1.91 mmol) with penta-acetyl 
glucopyranose 3 (0.500 g, 1.28 mmol) was achieved using Procedure C and afforded 19 as a 
white solid (0.416 g, 0.820 mmol, 64 %) after purification via gradient column chromatography 
(20-80 % ethyl acetate in hexane). 
   
 
M.p. 100-103 ºC. 1H NMR: H (CDCl3, 400 MHz) 6.41 (1H, d, J = 7.5 Hz, NHCOCH3), 5.21 (1H, t,         
J = 9.4 Hz, H-3’), 5.05 (1H, t, J = 9.6 Hz, H-4’), 4.96 (1H, dd, J = 10.1, 9.3 Hz, H-2’), 4.81 (1H, dt,         
J = 7.5, 5.4 Hz, H-2), 4.53 (1H, d, J = 10.1 Hz, H-1’), 4.23 (1H, dd, J = 12.6, 4.7 Hz, H-6’), 4.18    
(1H, dd, J = 12.6, 2.7 Hz, H-6’), 3.75 (3H, s, OCH3), 3.71 (1H, ddd, J = 10.1, 4.7, 2.7 Hz, H-5’), 3.20 
(1H, dd, J = 14.1, 4.9 Hz, H-3), 3.03 (1H, dd, J = 14.1, 6.0 Hz, H-3), [2.09, 2.05, 2.04, 2.01, 1.99  
(15H, 5s, 4 × COCH3, NHCOCH3)]. 13C NMR: C (CDCl3, 101 MHz) [171.1, 170.7, 170.1, 170.0, 
169.6, 169.5 (4 × COCH3, NHCOCH3, C-1)], 83.5 (C-1’), 76.4 (C-5’), 73.8 (C-3’), 70.1 (C-2’), 68.4          
(C-4’), 62.1, (C-6’), 52.8 (OCH3), 52.0 (C-2), 31.9 (C-3), 23.0 (NHCOCH3), 20.8 (2 × COCH3), 20.6                 













2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-α-D-glucopyranose (55) and 2-acetamido-1,3,4,6-
tetra-O-acetyl-2-deoxy-β-D-glucopyranose (52)66,85,86  
 
 
A suspension of 2-acetamido-2-deoxy-D-glucopyranose 54 (2.20 g, 9.95 mmol) in pyridine         
(14 mL) at room temperature, was treated with excess acetic anhydride (9.50 mL) and                     
the reaction mixture left to stir for 25 h. The reaction mixture was then diluted with 
dichloromethane (150 mL) and washed with aq. HCl (1.0 M, 300 mL). The extracted organic 
layer was dried over Na2SO4, filtered and solvents removed by azeotropic distillation after 
addition of toluene, to afford a white solid being composed of 2-acetamido-tetra-acetates 55 






α-anomer (55): M.p. 128-132 ºC (lit.86 128-130 ºC). 1H NMR: H (CDCl3, 400 MHz) 6.16 (1H, d,                      
J = 3.7 Hz, H-1), 5.61 (1H, d, J = 9.0 Hz, NHCOCH3), 5.25-5.16 (2H, m, H-3, H-4), 4.49-4.43 (1H, m, 
H-2), 4.23 (1H, dd, J = 12.4, 4.1 Hz, H-6), 4.05 (1H, dd, J = 12.4, 2.3 Hz, H-6), 3.98 (1H, ddd,            
J = 10.0, 4.1, 2.3 Hz, H-5), [2.17, 2.07, 2.03, 2.02 (12H, 4s, 4 × COCH3)], 1.91 (3H, s, NHCOCH3).            
13C NMR: C (CDCl3, 101 MHz) [171.8, 170.8, 170.1, 169.2, 168.7 (4 × COCH3, NHCOCH3)],                       
90.8 (C-1), 70.8 (C-3), 69.8 (C-5), 67.7 (C-4), 61.7 (C-6), 51.2 (C-2), 23.1 (NHCOCH3), [21.0, 20.8, 













To a solution of the anomeric mixture composed of 52 and 55 (2.00 g, 5.14 mmol) in 
dichloromethane (30 mL) at 55 ºC, was added TMSOTf (1.15 mL, 6.34 mmol) and the reaction 
mixture heated at reflux for 17 h. The reaction mixture was then cooled to room temperature, 
quenched (to pH = 8) by dropwise addition of triethylamine and concentrated under reduced 
pressure to give the crude product. This was then purified via gradient column chromatography                          
(1-5 % methanol in dichloromethane) and the pooled fractions concentrated under reduced 




1H NMR: H (CDCl3, 400 MHz) 5.96 (1H, d, J = 7.4 Hz, H-1), 5.26 (1H, t, J = 2.5 Hz, H-3), 4.93      
(1H, dq, J = 9.3, 1.2 Hz, H-4), 4.18 (1H, s, H-6), 4.17 (1H, d, J = 1.2 Hz, H-6), 4.15-4.10 (1H, m,      
H-2), 3.65-3.57 (1H, m, H-5), [2.10, 2.09 (6H, 2s, 2 × COCH3)], 2.08 (3H, d, J = 1.9 Hz, H-2’), 2.07    
(3H, s, COCH3). 13C NMR: C (CDCl3, 101 MHz) [170.6, 169.6, 169.2 (3 × COCH3)], 166.7 (C-1’), 
99.5 (C-1), 70.5 (C-4), 68.5 (C-3), 67.6 (C-5), 65.1 (C-2), 63.4 (C-6), [20.9, 20.8, 20.7 (3 × COCH3)],        














To a solution of 2-amino-2-deoxy-D-glucopyranose hydrochloride 58 (1.00 g, 4.64 mmol), K2CO3            
(1.40 g, 10.1 mmol) and CuSO4.5H2O (2.7 mol %) in methanol (25 mL) at room temperature, was 
added the sulfonyl azide 33 (1.16 g, 5.53 mmol) and the reaction mixture left to stir for 3 h.        
The reaction mixture was then concentrated under reduced pressure and the resulting residue 
re-dissolved in pyridine (8 mL) at room temperature, and treated with acetic anhydride              
(4.50 mL, 47.6 mmol). After stirring for 24 h the reaction mixture was quenched with crushed 
ice, extracted with ethyl acetate (4 x 40 mL) and the combined organic extracts washed 
sequentially with aq. HCl (1.0 M, 30 mL) and sat. brine (30 mL). The extracted organic layer was 
dried over Na2SO4, filtered and solvents removed by azeotropic distillation after addition of 
toluene to give the crude product. This was then purified via gradient column chromatography 
(30-80 % ethyl acetate in hexane) and the pooled fractions concentrated under reduced 
pressure to afford a colourless oil, which solidified upon storage at -18.0 ºC to afford 57 as a 
















 M.p. 95-96 ºC, (lit.70 96-97 ºC). IR: νmax (ATR, cm-1) 2113 (N=N=N), 1761 (C=O), 1747 (C=O), 1737 
(C=O), 1733 (C=O). 1H NMR: H (CDCl3, 400 MHz) 5.55 (1H, d, J = 8.6 Hz, H-1), 5.09 (1H, t,                
J = 9.4 Hz, H-3), 5.03 (1H, t, J = 9.4, H-4), 4.29 (1H, dd, J = 12.5, 4.6 Hz, H-6), 4.10 (1H, dd,              
J = 12.5, 2.2 Hz, H-6), 3.80 (1H, ddd, J = 9.7, 4.6, 2.2 Hz, H-5), 3.66 (1H, dd, J = 9.9, 8.6 Hz, H-2), 
[2.19, 2.09, 2.07, 2.02 (12H, 4s, 4 × COCH3)]. 13C NMR: C (CDCl3, 101 MHz) [170.6, 169.9,          
169.7, 168.7 (4 × COCH3)], 92.8 (C-1), 73.0, 72.9, 68.0, 62.8, 61.6 (C-6), [21.0, 20.8, 20.7,                                









methyl N-(tert-butoxycarbonyl)-L-serinate (62)87  
 
 
To a mixture of methyl L-serinate hydrochloride 23 (2.00 g, 12.9 mmol) in tetrahydrofuran         
(15 mL) and aq. NaHCO3 (2.3 M, 15 mL) at 0 ºC, was added Boc-anhydride (2.81 g, 12.9 mmol) 
and the reaction mixture allowed to warm to room temperature over 1 h. After a further 6 h       
the reaction mixture was concentrated under reduced pressure and the remaining                  
aqueous solution acidified (to pH = 3) by dropwise addition of aq. HCl (0.2 M) before extracting 
further with dichloromethane (3 x 30 mL). The combined organic extracts were washed with 
sat. brine (50 mL), dried over Na2SO4 and filtered. The filtrate was concentrated under reduced 
pressure to afford 62 as a colourless oil (2.55 g, 11.6 mmol, 90 %).  
 
1H NMR: H (CDCl3, 300 MHz) 5.51 (1H, d, J = 6.5, NHCOOR), 4.34 (1H, bs, H-2), 3.93 (1H, dd,           
J = 11.2, 4.0 Hz, H-3), 3.85 (1H, dd, J = 11.2, 3.7 Hz, H-3), 3.75 (3H, s, OCH3), 2.67 (1H, s, OH),                 
1.43 (9H, s, 3 × C(CH3)). 13C NMR: C (CDCl3, 101 MHz) 171.5 (C-1), 155.9 (NHCOOR), 80.4 














methyl (R)-2-((tert-butoxycarbonyl)amino)-3-iodopropanoate (60)74,88 
  
 
To a solution of imidazole (1.00 g, 14.7 mmol) and triphenylphosphine (3.86 g, 14.7 mmol) in 
dichloromethane (50 mL) at 0 ºC, was added iodine (3.73 g, 14.7 mmol) over a period of           
20 min in the dark. After a further 10 min the stirred reaction mixture was allowed to warm to 
room temperature over 20 min. The reaction mixture was then cooled to 0 ºC again before 
adding a solution of 62 (2.48 g, 11.3 mmol) in dichloromethane (10 mL) at 0 ºC, over a              
period of 1 h and then allowing the reaction mixture to warm to room temperature over 4 h.               
The reaction mixture was then diluted with a mixture of Et2O:Hex (1:1, 300 mL), filtered through 
a plug of silica and concentrated under reduced pressure to give a solid residue. The residue 
was re-suspended in diethyl ether (100 mL), filtered through a pad of Celite and concentrated 
under reduced pressure to give the crude product. This was then purified via flash column 
chromatography (100 % ethyl acetate) and the pooled fractions concentrated under pressure to 
give a colourless oil, which solidified upon storage at -18.0 ºC to afford 60 as a white solid                
(2.89 g, 8.78 mmol, 78 %).  
 
M.p. 44-45 °C, (lit.88 45-47 °C). 1H NMR: H (CDCl3, 300 MHz) 5.34 (1H, d, J = 6.6 Hz, NHCOOR),     
4.53-4.46 (1H, m, H-2), 3.79 (3H, s, OCH3), 3.60-3.51 (2H, m, H-3), 1.45 (9H, s, 3 × C(CH3)).          
13C NMR: C (CDCl3, 101 MHz) 170.2 (C-1), 155.0 (NHCOOR), 80.6 (C(CH3)3), 53.8, 53.1, 28.4         











2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (63)26  
 
 
To a solution of penta-acetyl glucopyranose 3 (5.00 g, 12.8 mmol) in dichloromethane (40 mL)    
at 0 ºC, was added HBr (33 % in AcOH, 30 mL) and the stirred reaction mixture allowed to warm 
to room temperature over 1 h. After a further 2 h the reaction mixture was diluted with water 
(150 mL), extracted with dichloromethane (4 x 150 mL) and the combined organic extracts 
basified (to pH = 7) through successive washes with sat. NaHCO3 (2 x 125 mL). The extracted 
organic layer was washed with sat. brine (200 mL), dried over Na2SO4 and filtered. The filtrate 
was then concentrated under reduced pressure and the resulting crude solid purified                          
via recrystallization from ethyl acetate and hexane to afford 63 as a white solid                                
(4.02 g, 9.78 mmol, 76 %).  
   
M.p. 80-82 ºC, (lit.26 81-83 ºC). 1H NMR: H (CDCl3, 400 MHz) 6.59 (1H, d, J = 4.1 Hz, H-1), 5.54 
(1H, t, J = 9.7 Hz, H-3), 5.14 (1H, t, J = 9.8 Hz, H-4), 4.82 (1H, dd, J = 9.8, 4.1 Hz, H-2), 4.33-4.25 
(2H, m, H-5, H-6), 4.15-4.07 (1H, m, H-6), [2.08, 2.07, 2.03, 2.01 (12H, 4s, 4 × COCH3)]. 13C NMR: 
C (CDCl3, 101 MHz) [170.6, 169.9, 169.8, 169.5 (4 × COCH3)], 86.7 (C-1), 72.3 (C-5), 70.7 (C-2), 
70.3 (C-3), 67.3 (C-4), 61.1 (C-6), 20.7 (2 × COCH3), 20.6 (2 × COCH3).26 
 
General procedure used for the conversion of glycosyl halides to isothiouronium salts  
 
Procedure (D): To a solution of the glycosyl halide (1.0 eq.) in dry acetone (20 mL) at room 
temperature, was added thiourea (1.5 eq.) and the reaction mixture heated at reflux for 2 h. 
The resulting precipitate was recovered by filtration and washed with small amounts of cold 
acetone to afford the desired isothiouronium salt product.26 
 












Glycosylation of thiourea (0.790 g, 10.4 mmol) with 63 (2.84 g, 6.91 mmol) was achieved using 
Procedure D and afforded 64 as a white solid (2.02 g, 4.15 mmol, 60 %). 
 
M.p. 186-190 ºC, (lit.89 191 ºC). 1H NMR: H (DMSO-d6, 400 MHz) 9.23 (2H, bs, NH2), 9.07                
(2H, bs, NH2), 5.68 (1H, d, J = 10.0 Hz, H-1), 5.31 (1H, t, J = 9.4 Hz, H-3), 5.16-5.06 (2H, m, H-2,    
H-4), 4.24-4.15 (2H, m, H-5, H-6), 4.12-4.06 (1H, m, H-6), [2.05, 2.02, 2.00, 1.98 (12H, 4s,                 
4 × COCH3)]. 13C NMR: C (DMSO-d6, 101 MHz) [170.0, 169.5, 169.3, 169.2 (4 × COCH3)], 166.3 
(CNH2NH2), 79.8 (C-1), 75.3 (C-5), 72.4 (C-3), 68.7 (C-2), 67.4 (C-4), 61.6 (C-6), [20.5, 20.4, 20.3 
20.2 (4 × COCH3)].26   
 
General procedure used for the conversion of isothiouronium salts to 1-thioglycopyranoses 
 
Procedure (E): To a suspension of the isothiouronium salt (1.0 eq.) in a DCM:H2O (2:1, 30 mL) 
mixture at room temperature, was added sodium metabisulfite (1.4 eq.) and the reaction 
mixture heated at 50 ºC for 3 h. The reaction mixture was then cooled to room temperature and 
the extracted aqueous layer re-extracted with dichloromethane (2 × 50 mL). The combined 
organic extracts were washed with sat. brine (100 mL), dried over Na2SO4 and filtered.                    
The filtrate was then concentrated under reduced pressure to give a colourless oil, which 













The hydrolysis of 64 (2.00 g, 4.10 mmol) was achieved using Procedure E and afforded 21 as a 




M.p. 72-74 ºC, (lit.26 69-70 ºC). 1H NMR: H (CDCl3, 300 MHz) 5.18 (1H, t, J = 9.3 Hz, H-3), 5.09 
(1H, t, J = 9.6 Hz, H-4), 4.96 (1H, t, J = 9.5 Hz, H-2), 4.54 (1H, t, J = 9.8 Hz, H-1), 4.24 (1H, dd,          
J = 12.5, 4.8 Hz, H-6), 4.12 (1H, dd, J = 12.5, 2.3 Hz, H-6), 3.71 (1H, ddd, J = 9.8, 4.8, 2.3 Hz, H-5), 
2.30 (1H, d, J = 9.9 Hz, SH), [2.08, 2.07, 2.01, 2.00 (12H, 4s, 4 × COCH3)]. 13C NMR: C (CDCl3,           
101 MHz) [170.8, 170.2, 169.7, 169.5 (4 × COCH3)], 78.9 (C-1), 76.5 (C-5), 73.7 (C-2, C-3), 68.3            




General procedure used for the conversion of 1-thioglycopyranoses to S-glycosylcysteines 
 
Procedure (F): To a solution of the 3-iodoproprionate 60 (1.1 eq.) and 1-thioglycopyranose 
derivative (1.0 eq.) in distilled ethyl acetate (20 mL) at room temperature, was added                       
aq. NaHCO3 (0.6 M, 20 mL) followed by TBAHS (4.0 eq.). The vigorously stirred reaction mixture 
was then heated at 40 ºC for 4 h, cooled to room temperature and the extracted aqueous                
layer re-extracted with ethyl acetate (2 × 40 mL). The combined organic extracts were washed 
sequentially with sat. NaHCO3 (50 mL) and sat. brine (50 mL), dried over Na2SO4 and filtered. 
The filtrate was concentrated under reduced pressure to give the crude product which was 
purified via column chromatography. The pooled fractions were then concentrated under 
reduced pressure to afford the desired S-glycosylcysteine product.24,27 
 
 





methyl N-(tert-butoxycarbonyl)-S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-                                









Glycosylation of the 3-iodoproprionate 60 (0.583 g, 1.77 mmol) with 21 (0.607 g, 1.67 mmol) 
was achieved using Procedure F and afforded 61 as a white solid (0.711 g, 1.26 mmol, 75 %), 
after purification via gradient column chromatography (60-100 % ethyl acetate in hexane).               
Note that this preparation of 61 was repeated and the two batches combined as a basis for          
the next step. 
   
M.p. 138-139 ºC. 1H NMR: H (CDCl3, 400 MHz) 5.65 (1H, d, J = 6.9 Hz, NHCOOR), 5.21 (1H, t,          
J = 9.3 Hz, H-3’), 5.09 (1H, t, J = 9.7 Hz, H-4’), 5.00 (1H, dd, J = 10.1, 9.3 Hz, H-2’), 4.53 (1H, bs,    
H-2), 4.50 (1H, d, J = 10.1 Hz, H-1’), 4.23 (1H, dd, J = 12.4, 4.8 Hz, H-6’), 4.16 (1H, dd, J = 12.4,     
2.4 Hz, H-6’), 3.73 (3H, s, OCH3), 3.71 (1H, ddd, J = 9.9, 4.8, 2.4 Hz, H-5’), 3.22 (1H, dd, J = 14.4, 
4.2 Hz, H-3), 2.97 (1H, dd, J = 14.4, 6.1 Hz, H-3), [2.10, 2.05, 2.02, 1.99 (12H, 4s, 4 × COCH3)], 
1.45 (9H, s, 3 × C(CH3)). 13C NMR: C (CDCl3, 101 MHz) [171.1, 170.8, 170.2, 169.5 (4 × COCH3,      
C-1)], 155.3 (NHCOOR), 83.2 (C-1’), 80.4 (C(CH3)3), 76.2 (C-5’), 73.9 (C-3’), 69.6 (C-2’),                     
68.3 (C-4’), 62.1 (C-6’), 53.6 (C-2), 52.7 (OCH3), 32.3 (C-3), 28.4 (3 × C(CH3)), 20.8 (2 × COCH3), 














General procedure used for the removal of the N-Boc protecting group  
 
Procedure (G): To a solution of the N-Boc protected substrate in dichloromethane (10 mL)              
at 0 ºC, was added TFA (2 mL) dropwise over a period of 30 min. The stirred reaction mixture 
was then allowed to warm to room temperature over 30 min and after a further 2 h excess         
TFA was evaporated off under a steady-stream of air.  The resulting residue was re-dissolved in 
methanol (10 mL) and solvents removed by azeotropic distillation after addition of toluene, to 






methyl S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-L-cysteinate trifluoroacetate (65) 
  
 
N-Boc deprotection of 61 (0.946 g, 1.67 mmol) was achieved using Procedure G and afforded 65 
as a colourless oil (1.08 g), which was taken forward to the next step without further drying.  
 
  
 1H NMR: H (D2O, 400 MHz) 5.44 (1H, t, J = 9.3 Hz, H-3’), 5.23-5.17 (2H, m, H-2’, H-4’), 4.96      
(1H, d, J = 10.1 Hz, H-1’), 4.52 (1H, dd, J = 7.5, 4.5 Hz, H-2), 4.44 (1H, dd, J = 12.8, 4.0 Hz, H-6’), 
4.32 (1H, dd, J = 12.8, 2.2 Hz, H-6’), 4.14 (2H, ddd, J = 10.1, 4.0, 2.2 Hz, H-5’), 3.94 (3H, s, OCH3), 
3.55 (1H, dd, J = 15.5, 4.5 Hz, H-3), 3.24 (1H, dd, J = 15.5, 7.5 Hz, H-3), [2.19, 2.18, 2.15,                   
2.13 (12H, 4s, 4 × COCH3)]. 13C NMR: C (D2O, 101 MHz) [173.6, 173.1, 172.8, 172.7, 168.7                     
(4 × COCH3, C-1], 82.1 (C-1’), 75.5 (C-5’), 73.8 (C-3’), 69.4 (C-2’), 68.0 (C-4’), 61.9 (C-6’), 53.9 
(OCH3), 53.1 (C-2), 29.2 (C-3), 20.2 (2 × COCH3), 20.0 (2 × COCH3). 19F NMR: F (D2O, 377 MHz)                
-75.5 (3F, s, COCF3). HRMS (ESI+): m/z calculated for C18H28NO11S+, 466.1378; found                        
466.1385 [M]+. Note the above analytical data was obtained from a separate experiment, 
conducted on a 200 mg scale, where the removal of residual solvent proved satisfactory. 
 













Amide coupling of 65 (1.08 g) with succinimidyl ester 45 (0.558 g, 1.70 mmol) was achieved 
using Procedure B and afforded 66 as a colourless oil (0.784 g, 1.16 mmol, 69 % over two steps) 
after purification via column chromatography (30-100 % hexane in ethyl acetate). 
 
1H NMR: H (CDCl3, 400 MHz) 6.41 (1H, d, J = 7.5 Hz, NHCOR), 5.19 (1H, t, J = 9.4 Hz, H-3’), 5.05 
(1H, t, J = 9.6 Hz, H-4’), 4.96 (1H, dd, J = 10.1, 9.4 Hz, H-2’), 4.79 (1H, ddd, J = 7.5, 6.2, 4.8 Hz,     
H-2), 4.64 (1H, bs, NHCOOR), 4.52 (1H, d, J = 10.1 Hz, H-1’), 4.21 (2H, dd, J = 12.5, 4.7 Hz, H-6’), 
4.16 (1H, dd, J = 12.5, 2.5 Hz, H-6’), 3.74 (3H, s, OCH3), 3.70 (1H, ddd, J = 9.9, 4.7, 2.5 Hz, H-5’), 
3.19 (1H, dd, J = 14.0, 4.8 Hz, H-3), 3.09 (1H, q, J = 6.4 Hz, H-6’’), 3.03 (1H, dd, J = 14.0, 6.2 Hz,  
H-3), 2.23 (2H, t, J = 7.5 Hz, H-2’’), [2.08, 2.04, 2.01, 1.99 (12H, 4s, 4 × COCH3)], 1.65 (1H, p,           
J = 7.4 Hz, H-3’’), 1.49 (1H, p, J = 7.5 Hz, H-5’’), 1.41 (9H, s, 3 × C(CH3)), 1.41-1.31 (1H, m, H-4’’).            
13C NMR: C (CDCl3, 101 MHz) [172.9, 171.1, 170.8, 170.2, 169.6, 169.5 (4 × COCH3, NHCOR,        
C-1], 156.2 (NHCOOR), 83.5 (C-1’), 79.2 (C(CH3)3), 76.3 (C-5’), 73.7 (C-3’), 69.9 (C-2’), 68.3 (C-4’), 
62.0 (C-6’), 52.9 (OCH3), 51.9 (C-2), 40.5 (C-6’’), 36.2 (C-2’’), 31.9 (C-3), 29.9 (C-5’’), 28.6                
(3 × C(CH3)), 26.5 (C-4’’), 25.2 (C-3’’), 20.8 (2 × COCH3), 20.7 (2 × COCH3). HRMS (ESI+): m/z 












General procedure used for the Zemplén deacetylation of glycosyl acetates 
 
Procedure (H): To a solution of the glycosyl acetate substrate (1.0 eq.) in methanol (8 mL) at 
room temperature, was added a methanolic solution of NaOMe (0.1 M, 1.0 eq.) and                   
the reaction mixture left to stir for 1 h. The reaction mixture was then diluted with                    
methanol, filtered through a pad of Celite and concentrated under reduced pressure to give a 
crude product. This was then purified via flash column chromatography (10 % methanol in ethyl 
acetate) and the pooled fractions concentrated under reduced pressure to afford the desired 
de-O-acetylated product which was taken directly forward to the next step.75 
  




Global deprotection of 66 (0.564 g, 0.831 mmol) was achieved using Procedure H, followed by 
Procedure E to afford 67 as an off-yellow oil (0.274 g, 0.522 mmol, 63 % over two steps).  
 
 
1H NMR: H (D2O, 300 MHz) 4.85 (1H, o*, H-2), 4.70 (1H, d, J = 9.8 Hz, H-1’), 4.06 (1H, dd,                  
J = 12.4, 1.7 Hz, H-6’), 3.94 (3H, s, OCH3), 3.88 (1H, dd, J = 12.4, 5.0 Hz, H-6’), 3.69-3.57                            
(3H, m, H-3’, H-4’, H-5’), 3.55-3.45 (2H, m, H-3, H-2’), 3.53-3.39 (3H, m, H-3, H-6’’), 2.52 (2H, t,                
J = 7.3 Hz, H-2’’), 1.90-1.77 (4H, m, H-3’’, H-5’’), 1.62-1.52 (2H, m, H-4’’). 13C NMR: C (D2O, 101 
MHz) 177.2, 172.9, 85.3 (C-1’), 80.5 (C-5’) 77.7 (C-3’), 72.7 (C-2’), 70.1 (C-4’), 61.5 (C-6’), 53.6 
(OCH3), 53.2 (C-2), 39.9 (C-6’’), 35.5 (C-2’’), 30.9 (C-3), 26.8 (C-5’’), 25.5 (C-4’’), 24.9 (C-3’’).                    
19F NMR: F (D2O, 377 MHz) -75.1 (3F, s, COCF3). HRMS (ESI+): m/z calculated for C16H31N2O8S+, 
411.1796; found 411.1800 [M]+. *Note that the multiplicity of this signal could not be assigned 
due to it being obscured by the residual D2O signal. This was due to the D2O signal shifting                   
over time, evident in two separate 1H NMR spectra obtained for the same prepared sample.                      
The 1H NMR spectra were instead referenced with respect to the OCH3 signal at 3.94 ppm.  

















To a solution of excess acetyl chloride (15 mL), fitted with a condenser at room temperature, 
was added 2-acetamido-2-deoxy-D-glucopyranose 54 (4.00 g, 18.1 mmol) and the reaction 
mixture heated at 30 ºC for 14 h. The reaction mixture was then cooled to 0 ºC, diluted with ice 
cold dichloromethane (150 mL) and quenched with ice cold water (100 mL). The extracted 
organic layer was washed sequentially with cold sat. NaHCO3 (3 × 100 mL) and cold sat. brine 
(150 mL), dried over Na2SO4 and filtered. The filtrate was then concentrated under reduced 
pressure to afford a white solid being composed of tri-O-acetate 69 and tetra-O-acetate 55 in 
approximated yields of (3.79 g, 10.4 mmol, 57 %) and (0.423 g, 1.09 mmol, 6 %) respectively, as 
judged from integration of their respective anomeric protons. 
 
  
Glycosyl chloride (69); 1H NMR: H (CDCl3, 300 MHz) 6.18 (1H, d, J = 3.7 Hz, H-1), 5.82 (1H, d,         
J = 8.7 Hz, NHCOCH3), 5.35-5.17 (2H, m, H-3, H-4), 4.53 (1H, ddd, J = 10.5, 8.7, 3.7 Hz, H-2),      
4.31-4.21 (2H, m, H-5, H-6), 4.15-4.08 (1H, m, H-6), [2.10, 2.05, 2.04 (9H, 3s, 3 × COCH3)], 1.98 
(3H, s, NHCOCH3). 13C NMR: C (CDCl3, 101 MHz) [171.6, 170.7, 170.2, 169.3 [(3 × COCH3, 
NHCOCH3)], 93.8 (C-1), 71.1 (C-5), 70.3 (C-3), 67.1 (C-4), 61.3 (C-6), 53.7 (C-2), 23.2 (NHCOCH3), 




















Glycosylation of thiourea (1.04 g, 13.7 mmol) with 3.71 g of the mixture composed of 55 and 69                
(≈ 3.34 g, 9.13 mmol) was achieved using Procedure D and afforded 70 as a white solid                   
(2.58 g, 5.84 mmol, ≈ 64 %).  
  
M.p. 171-172 ºC, (lit.26 177-178 ºC). 1H NMR: H (DMSO-d6, 300 MHz) 9.29 (4H, bs, 2 × NH2), 8.39 
(1H, d, J = 9.2 Hz, NHCOCH3), 5.67 (1H, d, J = 10.3 Hz, H-1), 5.14 (1H, t, J = 9.5 Hz, H-3), 4.93 (1H, 
t, J = 9.6 Hz, H-4), 4.28-3.95 (4H, m, H-2, H-5, 2 × H-6), [2.01, 1.98, 1.94 (9H, 3s, 3 × COCH3)], 
1.81 (3H, s, NHCOCH3). 13C NMR: C (DMSO-d6, 101 MHz) 170.0, 169.9, 169.6, 169.3 [(3 × COCH3, 
NHCOCH3)], 167.3 (CNH2NH2), 80.7 (C-1), 74.8 (C-5), 72.7 (C-3), 67.9 (C-4), 61.5 (C-6), 51.3 (C-2), 
22.5 (NHCOCH3), [20.6, 20.4, 20.3 (3 × COCH3)].26 










The hydrolysis of 70 (2.42 g, 5.48 mmol) was achieved using Procedure E and afforded 71 as a 
white solid (1.75 g, 4.82 mmol, 88 %). 
 
M.p. 143-146 ºC, (lit.26 145-146 ºC). 1H NMR: H (CDCl3, 300 MHz) 5.97 (1H, d, J = 9.4 Hz, 
NHCOCH3), 5.14-5.04 (2H, m, H-3, H-4), 4.60 (1H, t, J = 9.7 Hz, H-1), 4.21 (1H, dd, J = 12.4,          
4.8 Hz, H-6), 4.14-4.03 (2H, m, H-2, H-6), 3.69 (1H, ddd, J = 9.7, 4.8, 2.4 Hz, H-5), 2.53 (1H, d,               
J = 9.3 Hz, SH), [2.06, 2.01, 2.00 (9H, 3s, 3 × COCH3)], 1.96 (3H, s, NHCOCH3). 13C NMR: C                  
(CDCl3, 101 MHz) [171.2, 170.8, 170.6, 169.4 (3 × COCH3, NHCOCH3)], 80.3 (C-1), 76.3 (C-5), 73.6 
(C-3), 68.4 (C-4), 62.3 (C-6), 56.9 (C-2), 23.4 (NHCOCH3), [20.9, 20.8, 20.7 (3 × COCH3)].26 





methyl N-(tert-butoxycarbonyl)-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-         
glucopyranosyl)-L-cysteinate (68)77  
 








Glycosylation of the 3-iodoproprionoate 60 (1.37 g, 4.16 mmol) with 71 (1.40 g, 3.85 mmol) was 
achieved using Procedure F and afforded 68 as a white solid (1.63 g, 2.89 mmol, 75 %), after 
purification via gradient column chromatography (70-100 % ethyl acetate in hexane). 
 
M.p. 140-141 ºC. 1H NMR: H (CDCl3, 400 MHz) 5.74 (1H, d, J = 8.8 Hz, NHCOCH3), 5.69 (1H, d,       
J = 7.0 Hz, NHCOOR), 5.16-5.07 (2H, m, H-3’, H-4’), 4.59 (1H, d, J = 10.4 Hz, H-1’), 4.49 (1H, bs,   
H-2), 4.22 (1H, dd, J = 12.3, 5.0 Hz, H-6’), 4.18-4.10 (2H, m, H-2’, H-6’), 3.74 (3H, s, OCH3), 3.70 
(1H, ddd, J = 9.6, 5.0, 2.5 Hz, H-5’), 3.28 (1H, dd, J = 14.3, 3.8 Hz, H-3), 2.90 (1H, dd, J = 14.3,      
7.3 Hz, H-3), [2.10, 2.02, (9H, 2s, 3 × COCH3)], 1.94 (3H, s, NHCOCH3), 1.45 (9H, s, 3 × C(CH3)).             
13C NMR: C (CDCl3, 101 MHz) [171.3, 171.2, 170.8, 170.3, 169.4 (3 × COCH3, NHCOCH3, C-1)], 
155.5 (NHCOOR), 84.0 (C-1’), 80.4 (C(CH3)3), 76.3 (C-5’), 73.9 (C-3’), 68.4 (C-4’), 62.4 (C-6’),                
53.4 (C-2), 52.9 (C-2’), 52.7 (OCH3), 32.3 (C-3), 28.5 (3 × C(CH3)), 23.3 (NHCOCH3), [20.8, 20.7                 


















N-Boc deprotection of 68 (1.20 g, 2.13 mmol) was achieved using Procedure F and afforded 72 
as a colourless oil (1.42 g) which was taken forward to the next step without further drying. 
 
1H NMR: H (D2O, 400 MHz) 5.32 (1H, t, J = 9.4 Hz, H-3’), 5.15 (1H, t, J = 9.6 Hz, H-4’), 4.91 (1H, d, 
J = 10.5 Hz, H-1’), 4.51 (1H, dd, J = 7.7, 4.4 Hz, H-2), 4.44 (1H, dd, J = 12.8, 4.0 Hz, H-6’), 4.31     
(1H, dd, J = 12.8, 2.2 Hz, H-6’), 4.20 (1H, t, J = 10.3 Hz, H-2’), 4.09 (1H, ddd, J = 10.1, 4.0, 2.2 Hz, 
H-5’), 3.94 (3H, s, OCH3), 3.56 (1H, dd, J = 15.5, 4.4 Hz, H-3), 3.22 (1H, dd, J = 15.5, 7.7 Hz, H-3), 
[2.18, 2.14, 2.12 (9H, 3s, 3 × COCH3)], 2.04 (3H, s, NHCOCH3). 13C NMR: C (D2O, 101 MHz) 174.5, 
173.6, 173.2, 172.8, 168.7 (3 × COCH3, NHCOCH3, C-1), 83.1 (C-1’), 75.5 (C-5’), 73.7 (C-3’), 68.3 
(C-4’), 62.0 (C-6’), 53.9 (OCH3), 53.1 (C-2), 52.0 (C-2’), 29.3 (C-3), 21.9 (NHCOCH3), [20.2, 20.1, 
20.0 (3 × COCH3)]. 19F NMR: F (D2O, 400 MHz) -75.5 (3F, s, COCF3). HRMS (ESI+): m/z calculated 
for C18H28NO11S+, 465.1537; found 465.1537 [M]+. Note the above analytical data was obtained 



















Amide coupling of 72 (1.42 g) with succinimidyl ester 45 (0.732 g, 2.23 mmol) was achieved 
using Procedure B and afforded 73 as a white solid (1.13 g, 1.67 mmol, 78 % over two steps) 
after purification via column chromatography (70-100 % ethyl acetate in hexane).  
 
M.p. 162-164 °C. 1H NMR: H (CDCl3, 300 MHz) 6.58 (1H, d, J = 8.0 Hz, NHCOCH3), 6.13 (1H, d,       
J = 8.0 Hz, NHCOR), 5.18 (1H, t, J = 9.7 Hz, H-3’), 5.06 (1H, t, J = 9.7 Hz, H-4’), 4.82-4.76 (1H, m, 
H-2), 4.76 (1H, J = 10.1 Hz, H-1’), 4.65 (1H, bs, NHCOOR), 4.23 (1H, dd, J = 12.4, 4.9 Hz, H-6’), 
4.15 (1H, dd, J = 12.4, 2.5 Hz, H-6’), 4.05-3.97 (1H, m, H-2’), 3.75 (3H, s, OCH3), 3.70 (1H, ddd,        
J = 9.9, 4.9, 2.5 Hz, H-5’), 3.27 (1H, dd, J = 13.9, 4.0 Hz, H-3), 3.10 (1H, q, J = 6.6 Hz, H-6’’), 2.86 
(1H, dd, J = 13.9, 8.7 Hz, H-3), 2.27 (2H, t, J = 7.4 Hz, H-2’’), [2.08, 2.02, 2.00 (9H, 2s, 3 × COCH3)],                 
1.93 (3H, s, NHCOCH3), 1.66 (2H, J = 7.4 Hz, H-3’’), 1.49-1.31 (4H, m, H-4’’, H-5’’), 1.43 (9H, s,                       
3 × C(CH3)). 13C NMR: C (CDCl3, 101 MHz) [173.5, 171.2, 171.0, 170.8, 170.7, 169.5 (3 × COCH3, 
NHCOCH3, NHCOR, C-1)], 156.3 (NHCOOR), 83.6 (C-1’), 79.4 (C(CH3)3), 76.3 (C-5’), 73.9 (C-3’), 
68.5 (C-4’), 62.3 (C-6’), 53.3 (C-2’), 52.9 (OCH3), 51.1 (C-2), 40.7 (C-6’’), 36.3 (C-2’’), 32.2 (C-3), 
29.8 (C-5’’), 28.6 (3 × C(CH3)), 26.4 (C-4’’), 25.3 (C-3’’), 23.4 (NHCOCH3), [20.9, 20.8, 20.7                  











methyl N-(6-aminohexanoyl)-S-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-L-                     




Global deprotection of 73 (0.404 g, 0.596 mmol) was achieved using Procedure H, followed by 






1H NMR: H (D2O, 400 MHz) 4.82 (1H, dd, J = 8.9, 4.7 Hz, H-2), 4.80 (1H, J = 10.3, H-1’), 4.07                 
(1H, dd, J = 12.4, 1.6 Hz, H-6’), 3.95-3.88 (2H, m, H-2’, H-6’), 3.94 (3H, s, OCH3), 3.76-3.69 (1H, m, 
H-3’), 3.67-3.61 (2H, m, H-4’, H-5’), 3.50 (1H, dd, J = 14.2, 4.7 Hz, H-3), 3.19-3.10 (3H, m, H-3,     
H-6’’), 2.50 (2H, t, J = 7.4 Hz, H-2’’), 2.18 (3H, s, NHCOCH3), 1.88-1.77 (4H, m, H-3’’, H-5’’), 1.58                 
(2H, p, J = 7.4 Hz, H-4’’). 13C NMR: C (D2O, 101 MHz) 177.1, 174.7, 172.9, 84.2 (C-1’), 80.5                    
(C-5’), 75.5 (C-3’), 70.3 (C-4’), 61.4 (C-6’), 55.0 (C-2’), 53.5 (OCH3), 53.0 (C-2), 39.8 (C-6’’),                     
35.4 (C-2’’), 31.2 (C-3), 26.7 (C-5’’), 25.4 (C-4’’), 24.9 (C-3’’), 22.6 (NHCOCH3). 19F NMR: C (D2O, 
377 MHz) -74.9 (3F, s, COCF3). HRMS (ESI+): m/z calculated for C16H31N2O8S+, 452.2061; found 
452.2062 [M]+. Note the 1H NMR spectrum was referenced with respect to the OCH3 signal at 
3.94 ppm, for reasons discussed earlier. 
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Figure 22: The 1H NMR spectrum (1.90 - 6.60 ppm) of a partially purified sample of BGC 1. Key signals advocating 
for the presence of 1 have been assigned and are in good agreement with the reported literature values.7 
 
 
 
 
 
